NZ550448A - Pyrimidine derivatives for the treatment of abnormal cell growth - Google Patents

Pyrimidine derivatives for the treatment of abnormal cell growth

Info

Publication number
NZ550448A
NZ550448A NZ550448A NZ55044805A NZ550448A NZ 550448 A NZ550448 A NZ 550448A NZ 550448 A NZ550448 A NZ 550448A NZ 55044805 A NZ55044805 A NZ 55044805A NZ 550448 A NZ550448 A NZ 550448A
Authority
NZ
New Zealand
Prior art keywords
ylamino
pyrimidin
trifluoromethyl
dihydro
indol
Prior art date
Application number
NZ550448A
Inventor
Michael Joseph Luzzio
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ550448(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NZ550448A publication Critical patent/NZ550448A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Disclosed is a pharmaceutically acceptable salt of N-methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide, and the use of this salt for the treatment of cancer. Also disclosed are compounds of formula 1, and salts, solvates, and hydrates thereof, wherein the substituents are as defined in the specification, and also their use in treating abnormal cell growth such as cancer.

Description

<div class="application article clearfix" id="description"> <p class="printTableText" lang="en">New Zealand Paient Spedficaiion for Paient Number 550448 <br><br> -1- <br><br> PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Cross-Reference to Related Applications Reference is made to U.S. Patent Application Serial No. 60/435,670, filed December 20, 2002 (Attorney Docket No. PC25339), and U.S. Patent Application Serial No. 60/500,742, 5 filed September 5, 2003 (Attorney Docket No. PC25937). <br><br> Background of the Invention Described herein are pyrimidine derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Also described herein is a method of using such compounds in the treatment of abnormal cell growth in mammals, especially 10 humans, and to pharmaceutical compositions containing such compounds. <br><br> It is known that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene (i.e., a gene which, on activation, leads to the formation of malignant tumor cells). Many oncogenes encode proteins that are aberrant tyrosine kinases capable of causing cell transformation. Alternatively, the overexpression of a normal 15 proto-oncogenic tyrosine kinase may also result in proliferative disorders, sometimes resulting in a malignant phenotype. <br><br> Receptor tyrosine kinases are enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor, a transmembrane domain, and an intracellular portion which functions as a kinase to 20 phosphorylate specific tyrosine residues in proteins and hence to influence cell proliferation. Other receptor tyrosine kinases include c-erbB-2, c-met, tie-2, PDGFr, FGFr, and VEGFR. It is known that such kinases are frequently aberrantly expressed in common human cancers such as breast cancer, gastrointestinal cancer such as colon, rectal or stomach cancer, leukemia, and ovarian, bronchial or pancreatic cancer. It has also been shown that epidermal 25 growth factor receptor (EGFR), which possesses tyrosine kinase activity, is mutated and/or overexpressed in many human cancers such as brain, lung, squamous cell, bladder, gastric, breast, head and neck, oesophageal, gynecological and thyroid tumors. <br><br> Accordingly, it has been recognized that inhibitors of receptor tyrosine kinases are useful as selective inhibitors of the growth of mammalian cancer cells. For example, 30 erbstatin, a tyrosine kinase inhibitor, selectively attenuates the growth in athymic nude mice of a transplanted human mammary carcinoma that expresses epidermal growth factor receptor tyrosine kinase (EGFR) but is without effect on the growth of another carcinoma that does not express the EGF receptor. Thus, selective inhibitors of certain receptor tyrosine kinases, are useful in the treatment of abnormal cell growth, in particular cancer, in mammals. In addition 35 to receptor tyrosine kinses, selective inhibitors of certain non-receptor tyrosine kinases, such as FAK (focal adhesion kinase), Ick, src, abl or serine/threonine kinases (e.g., cyclin <br><br> -2- <br><br> dependent kinases), are useful in the treatment of abnormal cell growth, in particular cancer, in mammals. FAK is also known as the Protein-Tyrosine Kinase 2, PTK2. <br><br> Convincing evidence suggests that FAK, a cytoplasmic, non-receptor tyrosine kinase, plays an essential role in cell-matrix signal transduction pathways (Clark and Brugge 1995, 5 Science 268: 233-239) and its aberrant activation is associated with an increase in the metastatic potential of tumors (Owens et al. 1995, Cancer Research 55: 2752-2755). FAK was originally identified as a 125 kDa protein highly tyrosine-phosphorylated in cells transformed by v-Src. FAK was subsequently found to be a tyrosine kinase that localizes to focal adhesions, which are contact points between cultured cells and their underlying 10 substratum and sites of intense tyrosine phosphorylation. FAK is phosphorylated and, thus, activated in response to extracellular matrix (ECM)-binding to integrins. Recently, studies have demonstrated that an increase in FAK mRNA levels accompanied invasive transformation of tumors and attenuation of the expression of FAK (through the use of antisense oligonucleotides) induces apoptosis in tumor cells (Xu et al. 1996, Cell Growth and 15 Diff. 7: 413-418). In addition to being expressed in most tissue types, FAK is found at elevated levels in most human cancers, particularly in highly invasive metastases. <br><br> Various compounds, such as styrene derivatives, have also been shown to possess tyrosine kinase inhibitory properties. Five European patent publications, namely EP 0 566 226 A1 (published October 20, 1993), EP 0 602 851 A1 (published June 22, 1994), EP 0 635 20 507 A1 (published January 25, 1995), EP 0 635 498 A1 (published January 25, 1995), and EP 0 520 722 A1 (published December 30, 1992), refer to certain bicyclic derivatives, in particular quinazoline derivatives, as possessing anti-cancer properties that result from their tyrosine kinase inhibitory properties. <br><br> Also, World Patent Application WO 92/20642 (published November 26, 1992), refers 25 to certain bis-mono and bicyclic aryl and heteroaryl compounds as tyrosine kinase inhibitors that are useful in inhibiting abnormal cell proliferation. World Patent Applications W096/16960 (published June 6, 1996), WO 96/09294 (published March 6, 1996), WO 97/30034 (published August 21, 1997), WO 98/02434 (published January 22, 1998), WO 98/02437 (published January 22, 1998), and WO 98/02438 (published January 22, 1998), 30 also refer to substituted bicyclic heteroaromatic derivatives as tyrosine kinase inhibitors that are useful for the same purpose. In addition, the following list of publications relate to bis-mono and bicyclic aryl and heteroaryl compounds that may optionally be used as tyrosine kinase inhibitors: WO 03/030909, WO 03/032997, US Patent Application No. 2003/0181474, US Patent Application No. 2003/0162802, US Patent No. 5,863,924, WO 03/078404, US 35 Patent No. 4,507146, WO 99/41253, WO 01/72744, WO 02/48133, US Patent Application No. 2002/156087, WO 02/102783, and WO 03/063794. <br><br> -3- <br><br> U.S. Patent Application Serial No. 10/734,039, filed December 11, 2003 (Attorney Docket No. PC25339A) relates to a broad class of novel pyrimidine derivatives that are kinase inhibitors, and more specifically, inhibitors of FAK. Moreover, U.S. Patent Application Serial No. 10/733,215, filed December 11, 2003 (Attorney Docket No. PC25937A) relate more 5 specifically to a subset of pyrimidine derivatives, i.e., those bearing a 5-aminooxindole, which are tyrosine kinase inhibitors, and more particularly, FAK inhibitors. Compounds such as these are useful in the treatment of abnormal cell growth. <br><br> Accordingly, a need exists for additional selective inhibitors of certain receptor and non-receptor tyrosine kinases, useful in the treatment of abnormal cell growth, such as 10 cancer, in mammals. <br><br> It is an object of at least preferred embodiments of this invention to go some way towards meeting this need; and/or to at least provide the public with a useful choise. <br><br> Described herein are pyrimidine derivatives that are kinase inhibitors and inhibitors of the non-receptor tyrosine kinase, FAK, and are useful in the treatment of abnormal cell 15 growth. <br><br> In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that 20 such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art. <br><br> or a pharmaceutical^ acceptable salt, solvate, hydrate, or prodrug thereof, <br><br> wherein n is an integer from 1 to 3; <br><br> each R1 is a substituent independently selected from the group consisting of hydrogen, hydroxy, -(CrC6)alkyl, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -0(CrC6)alkyl, 30 -0(C3-C7)cycloalkyl, -0(C2-C9)heterocyclyl, -NR5R6, -SR7, -SOR7, -S02R7, -C02R12, -CONR5R6, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7; wherein said R1 substituents, -(CrC6)alkyl, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -0(CrC6)alkyl, -0(C3-C7)cycloalkyl, -0(C2-C9)heterocyclyl, -NR5R6, -SR7, -SOR7, -S02R7, -C02R12, -CONR5R6, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, are optionally substituted by one <br><br> Summary of the Invention Described herein is a compound of the formula 1 <br><br> R3^CR1R2)n <br><br> 25 <br><br> 1 <br><br> -4- <br><br> to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CF3, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and -CONR5R8; <br><br> each R2 is a substituent independently selected from the group consisting of 5 hydrogen, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, and -CONR5R6; wherein said R2 substituents, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, and -CONR5R6, are optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CF3, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, 10 -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; <br><br> 15 a cyclic group, -(C3-C10)cycloalkyl or -(C2-C9)heterocyclyl, wherein said cyclic group is optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CF3, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, 20 -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl moieties of said cyclic group may be optionally substituted by one to three R12 groups, and said cyclic group is optionally interrupted by one to three elements selected from the group consisting of-(C=0), -S02, -S-, -0-, -N-, -NH- and -NR12; <br><br> R1 and R2 may be taken together with the atom(s) to which they are attached to form <br><br> R3 is a substituent selected from the group consisting of: <br><br> 25 <br><br> (a) hydrogen; <br><br> 35 <br><br> 30 <br><br> (b) -(C6-C10)aryl or -(CrC9)heteroaryl, optionally substituted by one to three moieties independently selected from the group consisting of halogen, hydroxy, -(CrC6)alkyl, -(C1-C6)alkyl-P(0)(0(C1-C6)alkyl)2, -(C3-C10)cycloalkyl, (C6-C10)aryl, (C2-C9)heterocyclyl, -(CrC9)heteroaryl, -NR5R6, -NHS02(Cr C6)alkyl, -NHS02(C3-C6)cycloalkyl , -N((C1-C6)alkyl)(S02-C1-C6)alkyl), -N((Cr C6)alkyl)(S02(C3-C6)cycloalkyl), -N((C3-C6)cycloalkyl)(S02-CrC6)alkyl), <br><br> -N((C3-C6)cycloalkyl)(S02(C3-C6)cycloalkyl), -0(CrC6)alkyl, -0-S02(Cr C6)alkyl, -0-S02(C3-C6)cycloalkyl, -(CO)(CrC6)alkyl, -(CO)CF3, -(CO)(C3-C10)cycloalkyl, -(CO)(C6-C10)aryl, -(CO)(C2-C9)heterocyclyl, -(CO)(Cr C9)heteroaryl, -(C0)0(CrC6)alkyl, -(CO)O(C3-C10)cycloalkyl, -(C0)0(C6-C10)aryl, -(C0)0(C2-C9)heterocyclyl, -(CO)0(CrC9)heteroaryl, -(CO)(Cr C6)alkyl-0(CrC6)alkyl, -SO2(C-|-C0)alkyl, -SO2(C3-C0)cycloalkyl, -S02CF 3, <br><br> -SO2NH2, -S02NH(CrC6)alkyl, -S02NH(C3-C6)cycloalkyl, -S02N((Cr C6)alkyl)2, -S02N((CrC6)alkyl)((C3-C6)cycloalkyl), -S02N((C3-C6)cycloalkyl)2 and -S02NR5R6, wherein said -(C6-C10) aryl or -(CrC9) heteroaryl are optionally interrupted by one to three elements selected from the group consisting of-S-, -0-, -N-, -NH- and -NR12; <br><br> -(C3-C10)cycloalkyl, -(C2-C9)heterocyclyl, and -(CrC6)alkyl-(C2-C9) heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of halogen, hydroxy, -(CrC6)alkyl, -(Cr C6)alkyl-P(0)(0(C1-C6)alkyl)2, -(C3-C10)cycloalkyl, -(C6-C10)aryl, -(C2-C9)heterocyclyl, -(CrC9)heteroaryl, -NR5R6, -NS02(CrC6)alkyl, -NHS02(C3-C6)cycloalkyl, -N((C1-C6)alkyl)(S02-C1-C6)alkyl), -N((CrC6)alkyl)(S02(C3-C6)cycloalkyl), -N((C3-C6)cycloalkyl)(S02-CrC6)alkyl), -N((C3- <br><br> C6)cycloalkyl)(S02(C3-C6)cycloalkyl), -0(CrC6)alkyl, -0-S02(CrC6)alkyl, -O-S02(CrC6)alkyl, -O-SO2(O3-O0)cycloalkyl, -(OO)(O-|-O0)alkyl, -(CO)CF 3, -(CO)(C3-C10)cycloalkyl, -(CO)(C6-C10)aryl, -(CO)(C2-C9)heterocyclyl, -(CO)(CrC9)heteroaryl, -(C0)0(CrC6)alkyl, -(CO)O(C3-C10)cycloalkyl, -(CO)O(C6-C10)aryl, -(C0)0(C2-C9)heterocyclyl, -(CO)0(CrC9)heteroaryl, -(C0)(C1-C6)alkyl-0(C1-C6)alkyl, -S02(CrC6)alkyl, -S02(C3-C6)cycloalkyl, -S02CF 3, -S02NH2, -S02NH(CrC6)alkyl, -SO2NH(O3-O0)cycloalkyl, -S02N((CrC6)alkyl)2, -SO2N((C-|-C0)alkyl)((C3-C0)cycloalkyl), -S02N((C3-C6)cycloalkyl)2 and -S02NR5R6, wherein said -(C3-C10)cycloalkyl, -(C2-C9)heterocyclyl, and -(CrC6)alkyl-(C2-C9) heterocyclyl are optionally interrupted by one to three elements selected from the group consisting of -(C=0), -S02, -S-, -0-, -N-, -NH- and -NR12; <br><br> -(CrC6)alkyl optionally substituted by one to three moieties selected from the group consisting of halogen, hydroxy, -(CrC6)alkyl, -(C1-C6)alkyl-P(0)(0(C1-C6)alkyl)2, -(C3-C10)cycloalkyl, -(C6-C10)aryl, -(C2-C9)heterocyclyl, -(Cr C9)heteroaryl, -NR5R6, -NHS02(CrC6)alkyl, -NHS02(C3-C6)cycloalkyl, -N((Cr C6)alkyl)(S02-CrC6)alkyl), -N((CrC6)alkyl)(S02(C3-C6)cycloalkyl), -N((C3-C6)cycloalkyl)(S02-CrC6)alkyl), -N((C3-C6)cycloalkyl)(S02(C3-C6)cycloalkyl), -0(CrC6)alkyl, -0-S02(CrC6)alkyl, -0-S02(C3-C6)cycloalkyl, -(CO)(Cr C6)alkyl, -(CO)CF3, -(CO)(C3-C10)cycloalkyl, -(CO)(C6-C10)aryl, -(CO)(C2-C9)heterocyclyl, -(CO)(CrC9)heteroaryl, -(C0)0(CrC6)alkyl, -(C0)0(C3-C10)cycloalkyl, -(CO)O(C6-C10)aryl, -(C0)0(C2-C9)heterocyclyl, -(C0)0(Cr C9)heteroaryl, -(C0)(C1-C6)alkyl-0(C1-C6)alkyl, -S02(CrC6)alkyl, -S02(C3-C6)cycloalkyl, -S02CF 3, -S02NH2, -SO2NH(O-|-O0)alkyl, -S02NH(03-C6)cycloalkyl, -S02N((CrC6)alkyl)2, -S02N((CrC6)alkyl)((C3-C6)cycloalkyl), <br><br> -6- <br><br> -S02N((C3-C6)cycloalkyl)2 and -S02NR5R6, wherein said -(CrC6)alkyl is optionally interrupted by one to three elements selected from the group consisting of-(C=0), -S02, -S-, -0-, -N-, -NH- and -NR12; <br><br> and wherein each R3 (b)-(d) substituent, moiety, or element is optionally substituted 5 by one to three radicals independently selected from the group consisting of hydrogen, halogen, hydroxy, -CF3, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -(C6-C10)aryl, -(CrC9)heteroaryl, -0(CrC6)alkyl, -0(C3-C7)cycloalkyl, -0(C2-C9)heterocyclyl, -C=N-OH, -C=N-0(CrC6 alkyl), -NR5R6, -SR7, -SOR7, -S02R7, -C02R12, -CONR5R6, - S02NR5R6, -NHCOR5, -NR12CONR5R6, and -NR12S02R7; 10 R4 is a substituent selected from the group consisting of hydrogen, -(CrC6)alkyl, -(C3- <br><br> C7)cycloalkyl, and -(C2-C9)heterocyclyl; wherein said -(CrC6)alkyl, -(C3-C7)cycloalkyl, and -(C2-C9)heterocyclyl R4 substituents are optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxyl, -(Cr C6)alkyl, -CN, -NR5R6, -OR5, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -S02NR5R6, 15 -NR12S02R7, -S02R7 and -CONR5R8; wherein R5 and R8 of said -CONR5R8 group may be taken together with the atoms to which they are attached to form a -(C2-C9)heterocyclyl; <br><br> R5 and R6 are each substituents independently selected from the group consisting of hydrogen, -(CrC6)alkyl, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -(C6-C10)aryl, -(Cr C9)heteroaryl, -COR12 and -S02R12; wherein said -(CrC6)alkyl, -(C3-C7)cycloalkyl, -(C2-20 C9)heterocyclyl, -(C6-C10)aryl, -(CrC9)heteroaryl, -COR12 and -S02R12 R5 or R6 substituents are optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, -CF3, -CN, -(CrC6)alkyl, -NH(CrC6)alkyl, -NH(C3-C7)cycloalkyl, -NH(C2-C9)heterocyclyl, -NH(C6-C10)aryl, -NH(CrC9)heteroaryl -N((Cr C6)alkyl)2, -N((C3-C7)cycloalkyl)2, -N((C2-C9)heterocyclyl)2, -N((C6-C10)aryl)2, -N((Cr 25 C9)heteroaryl)2 , -0(CrC6)alkyl, -0(C3-C7)cycloalkyl, -0(C2-C9)heterocyclyl, -O(C6-C10)aryl, -O^-i-CgJheteroaryl, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R7, S02NR5R6, NR12S02R7, -S02R7 -CONH2, -CONHR7, and -CONR7R8; wherein R7 and R8 of said -CONR7R8 group may be taken together with the nitrogen atom to which they are attached to form a -(C2-C9) heterocyclyl; <br><br> 30 R5 and R6 may be taken together with the atom(s) to which they are attached to form a -(C2-C9)heterocyclyl, wherein said -(C2-C9)heterocyclyl group is optionally substituted by one to three moieties selected from the group consisting of hydrogen, halogen, hydroxy, -CF3, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((Cr C6)alkyl), -NR7R8, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR7R8, 35 -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR7R8, -NHCOR12, -NR12CONR7R8, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl moieties of said -(C2-C9)heterocyclyl group may be optionally substituted by one to three R7 groups, and said -(C2-C9)heterocyclyl group <br><br> -7- <br><br> is optionally interrupted by one to three elements selected from the group consisting of -(C=0), -S02, -S-, -0-, -N-, -NH- and -NR12; <br><br> R7 is a substituent selected from the group consisting of -(CrC6)alkyl, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -(C6-C10)aryl, and -(CrC9) heteroaryl; wherein said -(Cr 5 C6)alkyl, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -(C6-C10)aryl, and -(CrC9) heteroaryl R7 substituents are optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR122, and -0(Cr C6)alkyl; <br><br> R8 is a substituent selected from the group consisting of hydrogen, -(CrC6)alkyl, -(C3-10 C7)cycloalkyl, -(C2-C9)heterocyclyl, -(C6-C10)aryl, and -(CrC9) heteroaryl; wherein said -(Cr C6)alkyl, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -(C6-C10)aryl, and -(CrC9) heteroaryl R8 substituents are optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NH2, -NHR9, -NR92, OR9, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R1°, -CONH2, -CONHR10, and -CONR10R11; <br><br> 10 11 1011 <br><br> 15 wherein R and R of -CONR R may be taken together with the nitrogen atom to which they are attached to form a -(C2-C9)heterocyclyl; <br><br> R9 and R10 are each -(CrC6)alkyl; <br><br> R11 is hydrogen or-(CrC6)alkyl; and <br><br> R12 is a substituent selected from the group consisting of hydrogen, -(CrC6)alkyl, 20 -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -(C6-C10)aryl, and -(CrC9)heteroaryl; wherein said -(CrC6)alkyl, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -(C6-C10)aryl, and -(CrC9)heteroaryl R12 substituent is optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, -CF3, -CN, -(CrC6)alkyl, -NH(CrC6)alkyl, -NH(C3-C7)cycloalkyl, -NH(C2-C9)heterocyclyl, -NH(C6-C10)aryl, -NH(CrC9)heteroaryl -N((Cr 25 C6)alkyl)2, -N((C3-C7)cycloalkyl)2, -N((C2-C9)heterocyclyl)2, -N((C6-C10)aryl)2, -N((Cr C9)heteroaryl)2 , -0(CrC6)alkyl, -0(C3-C7)cycloalkyl, -0(C2-C9)heterocyclyl, -O(C6-C10)aryl, -O^-i-CgJheteroaryl, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R7, -CONH2, -CONHR7, and -CONR7R8; wherein R7 and R8 of said -CONR7R8 group may be taken together with the atoms to which they are attached to form a -(C2-C9) heterocyclyl. <br><br> 30 Also described herein are isotopically-labeled compounds, which are identical to those recited in Formula 1, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, 35 such as 2H, 3H, 13C, 14C, 15N, 180, 170, 31P, 32P, 35S, 18F, and 36CI, respectively. Compounds, prodrugs thereof, and pharmaceutical^ acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are <br><br> -8- <br><br> contemplated herein. Certain isotopically-labelled compounds, for example those into which <br><br> 3 14 <br><br> radioactive isotopes such as H and C are incorporated, are useful in drug and/or substrate <br><br> 3 14 <br><br> tissue distribution assays. Tritiated, i.e., H, and carbon-14, i.e., C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier 5 isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically-labelled compounds of Formula 1 and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by 10 substituting a readily available isotopically-labelled reagent for a non-isotopically-labelled reagent. <br><br> Also described herein are pharmaceutically acceptable acid addition salts of compounds of the formula 1. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are 15 those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-20 naphthoate)]salts. <br><br> Also described are base addition salts of formula 1. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula 1 that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such 25 pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines. <br><br> The phrase "pharmaceutically acceptable salt(s)", as used herein, unless otherwise 30 indicated, includes salts of acidic or basic groups which may be present in the compounds. The compounds that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of are those that form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable anions, such as the 35 hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, <br><br> -9- <br><br> formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [Le., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts. The compounds that include a basic moiety, such as an amino group, may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above. <br><br> 5 Also described are pharmaceutical compositions containing prodrugs of compounds of the formula 1. Compounds of formula 1 having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of 10 compounds of formula 1. The amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters 15 that are covalently bonded to the above substituents of formula 1 through the carbonyl carbon prodrug sidechain. <br><br> Also described are compounds of formula 1 containing protective groups. One skilled in the art will also appreciate that compounds can also be prepared with certain protecting groups that are useful for purification or storage and can be removed before administration to 20 a patient. The protection and deprotection of functional groups is described in "Protective Groups in Organic Chemistry", edited by J.W.F. McOmie, Plenum Press (1973) and "Protective Groups in Organic Synthesis", 3rd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1999). <br><br> All stereoisomers (e.g., cis and trans isomers) and all optical isomers of compounds of 25 the formula 1 (e.g., R and S enantiomers), as well as racemic, diastereomeric and other mixtures of such isomers of the compounds are contemplated herein. <br><br> The compounds, salts and prodrugs can exist in several tautomeric forms, including the enol and imine form, and the keto and enamine form and geometric isomers and mixtures thereof. All such tautomeric forms are included within the scope of the present invention. 30 Tautomers exist as mixtures of a tautomeric set in solution. In solid form, usually one tautomer predominates. Even though one tautomer may be described, all tautomers of the compounds are contemplated herein. <br><br> Also described are atropisomers of the compounds. Atropisomers refer to compounds of formula 1 that can be separated into rotationally restricted isomers. 35 The compounds may contain olefin-like double bonds. When such bonds are present, <br><br> the compounds exist as cis and trans configurations and as mixtures thereof. <br><br> -10- <br><br> A "suitable substituent" is intended to mean a chemically and pharmaceutically acceptable functional group i.e., a moiety that does not negate the biological activity of the inventive compounds. Such suitable substituents may be routinely selected by those skilled in the art. Illustrative examples of suitable substituents include, but are not limited to halo groups, 5 perfluoroalkyl groups, perfluoroalkoxy groups, alkyl groups, alkenyl groups, alkynyl groups, hydroxy groups, oxo groups, mercapto groups, alkylthio groups, alkoxy groups, aryl or heteroaryl groups, aryloxy or heteroaryloxy groups, aralkyi or heteroaralkyi groups, aralkoxy or heteroaralkoxy groups, H0-(C=0)- groups, amino groups, alkyl- and dialkylamino groups, carbamoyl groups, alkylcarbonyl groups, alkoxycarbonyl groups, alkylaminocarbonyl groups 10 dialkylamino carbonyl groups, arylcarbonyl groups, aryloxycarbonyl groups, alkylsulfonyl groups, arylsulfonyl groups and the like. Those skilled in the art will appreciate that many substituents can be substituted by additional substituents. Further examples of suitable substituents include those recited in the definition of compounds of Formula 1, including R1 through R12, as defined hereinabove. <br><br> 15 The term "interrupted by" refers to compounds in which a ring carbon atom is replaced by an element selected from the group consisting of -(C=0), -S02, -S-, -0-, -N-, -NH-, and -NR12. For example, if a substituent is -(C6-C10)aryl, such as the ring may be interrupted or replaced by a nitrogen heteroatom to form the following <br><br> 20 ring: <br><br> such that a ring carbon is replaced by the heteroatom nitrogen. Compounds described herein can accommodate up to three such replacements or interruptions. <br><br> As used herein, the term "alkyl," as well as the alkyl moieties of other groups referred 25 to herein (e.g., alkoxy), may be linear or branched (such as methyl, ethyl, n-propyl, /'sopropyl, n-butyl, /'so-butyl, secondary-butyl, ferf/'a/y-butyl); optionally substituted by 1 to 3 suitable substituents as defined above such as fluoro, chloro, trifluoromethyl, (CrC6)alkoxy, (C6-C10)aryloxy, trifluoromethoxy, difluoromethoxy or (CrC6)alkyl. The phrase "each of said alkyl" as used herein refers to any of the preceding alkyl moieties within a group such alkoxy, 30 alkenyl or alkylamino. Preferred alkyls include (CrC6)alkyl, more preferred are (CrC4)alkyl, and most preferred are methyl and ethyl. <br><br> -11- <br><br> As used herein, the term "cycloalkyl" refers to a mono, bicyclic or tricyclic carbocyclic ring (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclopentenyl, cyclohexenyl, bicyclo[2.2.1]heptanyl, bicyclo[3.2.1]octanyl and bicyclo[5.2.0]nonanyl, etc.); optionally containing 1 or 2 double bonds and optionally substituted 5 by 1 to 3 suitable substituents as defined above such as fluoro, chloro, trifluoromethyl, (CrC6)alkoxy, (C6-C10)aryloxy, trifluoromethoxy, difluoromethoxy or (CrC6)alkyl. <br><br> As used herein, the term "halogen" includes fluoro, chloro, bromo or iodo or fluoride, chloride, bromide or iodide. <br><br> As used herein, the term "alkenyl" means straight or branched chain unsaturated 10 radicals of 2 to 6 carbon atoms, including, but not limited to ethenyl, 1-propenyl, 2-propenyl (allyl), /'so-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like; optionally substituted by 1 to 3 suitable substituents as defined above such as fluoro, chloro, trifluoromethyl, (CrC6)alkoxy, (C6-C10)aryloxy, trifluoromethoxy, difluoromethoxy or (CrC6)alkyl. <br><br> As used herein, the term "alkynyl" is used herein to mean straight or branched 15 hydrocarbon chain radicals having one triple bond including, but not limited to, ethynyl, propynyl, butynyl, and the like; optionally substituted by 1 to 3 suitable substituents as defined above such as fluoro, chloro, trifluoromethyl, (CrC6)alkoxy, (C6-C10)aryloxy, trifluoromethoxy, difluoromethoxy or (CrC6)alkyl. <br><br> As used herein, the term "carbonyl" or "(C=0)" (as used in phrases such as 20 alkylcarbonyl, alkyl-(C=0)- or alkoxycarbonyl) refers to the joinder of the &gt;C=0 moiety to a second moiety such as an alkyl or amino group (i.e. an amido group). Alkoxycarbonylamino (i.e. alkoxy(C=0)-NH-) refers to an alkyl carbamate group. The carbonyl group is also equivalently defined herein as (C=0). Alkylcarbonylamino refers to groups such as acetamide. <br><br> 25 As used herein, the term "aryl" means aromatic radicals such as phenyl, naphthyl, <br><br> tetrahydronaphthyl, indanyl and the like; optionally substituted by 1 to 3 suitable substituents as defined above. <br><br> As used herein, the term "heteroaryl" refers to an aromatic heterocyclic group usually with one heteroatom selected from O, S and N in the ring. In addition to said heteroatom, the 30 aromatic group may optionally have up to four N atoms in the ring. For example, heteroaryl group includes pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, imidazolyl, pyrrolyl, oxazolyl (e.g., 1,3-oxazolyl, 1,2-oxazolyl), thiazolyl (e.g., 1,2-thiazolyl, 1,3-thiazolyl), pyrazolyl, tetrazolyl, triazolyl (e.g., 1,2,3-triazolyl, 1,2,4-triazolyl), oxadiazolyl (e.g., 1,2,3-oxadiazolyl), thiadiazolyl (e.g., 1,3,4-thiadiazolyl), quinolyl, isoquinolyl, benzothienyl, benzofuryl, indolyl, 35 and the like; optionally substituted by 1 to 3 suitable substituents as defined above such as fluoro, chloro, trifluoromethyl, (CrC6)alkoxy, (C6-C10)aryloxy, trifluoromethoxy, difluoromethoxy or (CrC6)alkyl. <br><br> -12- <br><br> The term "heterocyclic" as used herein refers to a cyclic group containing 1-9 carbon atoms and 1 to 4 hetero atoms selected from N, O, S(0)n or NR. Examples of such rings include azetidinyl, tetrahydrofuranyl, imidazolidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, thiomorpholinyl, tetrahydrothiazinyl, tetrahydro-5 thiadiazinyl, morpholinyl, oxetanyl, tetrahydrodiazinyl, oxazinyl, oxathiazinyl, indolinyl, isoindolinyl, quinuclidinyl, chromanyl, isochromanyl, benzoxazinyl, and the like. Examples of said monocyclic saturated or partially saturated ring systems are tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-4-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperazin-1-yl, 10 piperazin-2-yl, piperazin-3-yl, 1,3-oxazolidin-3-yl, isothiazolidine, 1,3-thiazolidin-3-yl, <br><br> 1.2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, thiomorpholin-yl, 1,2-tetrahydrothiazin-2-yl, <br><br> 1.3-tetrahydrothiazin-3-yl, tetrahydrothiadiazin-yl, morpholin-yl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, 1,4-oxazin-2-yl, 1,2,5-oxathiazin-4-yl and the like; optionally containing 1 or 2 double bonds and optionally substituted by 1 to 3 suitable substituents as <br><br> 15 defined above such as fluoro, chloro, trifluoromethyl, (CrC6)alkoxy, (C6-C10)aryloxy, trifluoromethoxy, difluoromethoxy or (CrC6)alkyl. <br><br> Nitrogen heteroatoms as used herein refers to N=, &gt;N and -NH; wherein -N= refers to a nitrogen double bond; &gt;N refers to a nitrogen containing two bond connections and -N refers to a nitrogen containing one bond. <br><br> 20 "Embodiment" as used herein refers to specific groupings of compounds or uses into discrete subgenera. Such subgenera may be cognizable according to one particular substituent such as a specific R1 or R3 group. Other subgenera are cognizable according to combinations of various substituents, such as all compounds wherein R2 is hydrogen and R1 is (CrC6)alkyl. <br><br> 25 Described herein is a compound of formula 1_, wherein R3 is hydrogen. <br><br> Also described is a compound of formula 1_ wherein R3 is selected from the group consisting of -(C6-C10)aryl and -(CrC9)heteroaryl, optionally substituted by one to three moieties independently selected from the group consisting of halogen, hydroxy, -(CrC6)alkyl, -(C1-C6)alkyl-P(0)(0(C1-C6)alkyl)2, -(C3-C10)cycloalkyl, (C6-C10)aryl, (C2-C9)heterocyclyl, -(Cr 30 C9)heteroaryl, -NR5R6, -NHS02(CrC6)alkyl, -NHS02(C3-C6)cycloalkyl, -N((CrC6)alkyl)(S02-CrC6)alkyl), -N((CrC6)alkyl)(S02(C3-C6)cycloalkyl), -N((C3-C6)cycloalkyl)(S02-CrC6)alkyl), -N((C3-C6)cycloalkyl)(S02(C3-C6)cycloalkyl), -0(CrC6)alkyl, -0-S02(CrC6)alkyl, -0-S02(C3-C6)cycloalkyl, -(CO)(CrC6)alkyl, -(CO)CF3, -(CO)(C3-C10)cycloalkyl, -(CO)(C6-C10)aryl, -(CO)(C2-C9)heterocyclyl, -(CO)(CrC9)heteroaryl, -(C0)0(CrC6)alkyl, -(C0)0(C3-35 C10)cycloalkyl, -(CO)O(C6-C10)aryl, -(C0)0(C2-C9)heterocyclyl, -(CO)0(CrC9)heteroaryl, -(C0)(C1-C6)alkyl-0(C1-C6)alkyl, -SO2(O-|-O0)alkyl, -SO2(C3-C0)cycloalkyl, S020F3, S02NH2, S02NH(CrC6)alkyl, -SO2NH(O3-O0)cycloalkyl, -SO2N((O-|-O0)alkyl)2, SO2N((O-|-O0)alkyl)((O3- <br><br> -13- <br><br> C6)cycloalkyl), -S02N((C3-C6)cycloalkyl)2 and -S02NR5R6, wherein said -(C6-C10) aryl or -(Cr C9) heteroaryl are optionally interrupted by one to three elements selected from the group consisting of-S-, -0-, -N-, -NH- and -NR12. <br><br> Another embodiment is a compound of formula 1_ wherein R3 is selected from the 5 group consisting of -(C3-C10)cycloalkyl, -(C2-C9)heterocyclyl, and -(CrC6)alkyl-(C2-C9) heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of halogen, hydroxy, -(C-|-C6)alkyl, -(C1-C6)alkyl-P(0)(0(C1-C6)alkyl)2, -(C3-C10)cycloalkyl, (C6-C10)aryl, (C2-C9)heterocyclyl, -(C-|-C9)heteroaryl, -NR5R6, -NS02(Cr C6)alkyl, -NHS02(C3-C6)cycloalkyl, -N((C1-C6)alkyl)(S02-C1-C6)alkyl), -N((CrC6)alkyl)(S02(C3-10 C6)cycloalkyl), -N((C3-C6)cycloalkyl)(S02-CrC6)alkyl), -N((C3-C6)cycloalkyl)(S02(C3-C6)cycloalkyl), -O(O-|-O0)alkyl, -O-SO2(O-|-O0)alkyl, -O-SO2(O-|-O0)alkyl, -0-S02(03-C6)cycloalkyl, -(CO)(CrC6)alkyl, -(CO)CF3, -(CO)(C3-C10)cycloalkyl, -(CO)(C6-C10)aryl, -(CO)(C2-C9)heterocyclyl, -(CO)(CrC9)heteroaryl, -(C0)0(CrC6)alkyl, -(C0)0(C3-C10)cycloalkyl, -(CO)O(C6-C10)aryl, -(C0)0(C2-C9)heterocyclyl, -(CO)0(CrC9)heteroaryl, 15 -(C0)(C1-C6)alkyl-0(C1-C6)alkyl, -S02(C-|-C6)alkyl, -S02(C3-C6)cycloalkyl, S02CF3, S02NH2, S02NH(CrC6)alkyl, -S02NH(C3-C6)cycloalkyl, -S02N((CrC6)alkyl)2, S02N((CrC6)alkyl)((C3-C6)cycloalkyl), -S02N((C3-C6)cycloalkyl)2 and -S02NR5R6, wherein said -(C3-C10)cycloalkyl, -(C2-C9)heterocyclyl, and -(CrC6)alkyl-(C2-C9) heterocyclyl are optionally interrupted by one to three elements selected from the group consisting of -(C=0), -S02, -S-, -0-, -N-, -NH- and 20 -NR12. <br><br> A further embodiment is a compound of formula 1_ wherein R3 is -(C-|-C6)alkyl optionally substituted by one to three moieties selected from the group consisting of halogen, hydroxy, -(C-|-C6)alkyl, -(C1-C6)alkyl-P(0)(0(C1-C6)alkyl)2, -(C3-C10)cycloalkyl, (C6-C10)aryl, (C2-C9)heterocyclyl, -(C-|-C9)heteroaryl, -NR5R6, -NHS02(C-|-C6)alkyl, -NHS02(C3-25 C6)cycloalkyl, -N((C1-C6)alkyl)(S02-C1-C6)alkyl), -N((CrC6)alkyl)(S02(C3-C6)cycloalkyl), -N((C3-C6)cycloalkyl)(S02-CrC6)alkyl), -N((C3-C6)cycloalkyl)(S02(C3-C6)cycloalkyl), -0(Cr C6)alkyl, -0-S02(CrC6)alkyl, -O-SO2(O3-O0)cycloalkyl, -(OO)(O-|-O0)alkyl, -(OO)OF3, -(00)(03-C10)cycloalkyl, -(CO)(C6-C10)aryl, -(CO)(C2-C9)heterocyclyl, -(CO)(CrC9)heteroaryl, -(00)0(0-1-C6)alkyl, -(00)0(C3-C-io)cycloalkyl, -(CO)O(C0-C-io)aryl, -(C0)0(C2-30 C9)heterocyclyl, -(CO)0(C-|-C9)heteroaryl, -(C0)(C1-C6)alkyl-0(C1-C6)alkyl, -S02(C-|-C6)alkyl, -S02(03-C6)cycloalkyl, S02CF3, S02NH2, S02NH(C-|-C6)alkyl, -S02NH(C3-C6)cycloalkyl, -S02N((C-|-C6)alkyl)2, S02N((C1-C6)alkyl)((C3-C6)cycloalkyl), -S02N((C3-C6)cycloalkyl)2 and -S02NR5R6, wherein said -(C-|-C6)alkyl is optionally interrupted by one to three elements selected from the group consisting of-(0=0), -S02, -S-, -0-, -N-, -NH- and -NR12. 35 Also described is a compound of formula 2 <br><br> -14- <br><br> CFa <br><br> N "N A H <br><br> wherein A is selected from the group consisting of: <br><br> X./ <br><br> X,/ <br><br> X./ <br><br> '(R")m wherein m is an integer from 0 to 3 and R13 is a substituent selected from the group consisting of hydrogen, halogen, hydroxy, (C-|-C6)-alkyl, (C3-C7)-cycloalkyl, (C6-C10)-aryl, (Cr 10 C9)heteroaryl, (C2-C9)-heterocyclyl, 0-(C-|-C6)-alkyl, 0-(C3-C7)-cycloalkyl, S02-(C-|-C6)alkyl, S02(C3-C7)-cycloalkyl, NHS02(CrC6)alkyl, N((C1-C6)alkyl)(S02(C1-C6-alkyl)), N((C3-C7)cycloalkyl)(S02(CrC6-alkyl)), N(CrC6-alkyl)(S02(C3-C7)cycloalkyl), N((C3- <br><br> -15- <br><br> C7)cycloalkyl)(S02(C3-C7)cycloalkyl), 0S02(CrC6)alkyl, S02CF3, S02NH2, S02NH(Cr C6)alkyl, S02NH(C3-C7)cycloalkyl, S02NR5R6, S02N((CrC6)alkyl)2, CF3, CO-(CrC6)alkyl, CO-(C3-C7)cycIoaIkyI, OOOF3, OO2(O-|-O0)BlkyI, <br><br> x o,s and <br><br> Another embodiment is a compound of the formula 3 <br><br> H <br><br> o=:N-n j[VF3 <br><br> N^N B H <br><br> wherein B is selected from the group consisting of: <br><br> -16- <br><br> -(R <br><br> -/ (R <br><br> X/ <br><br> •* M <br><br> Also described is a compound of formula 4 <br><br> wherein D is selected from the group consisting of: <br><br> -18- <br><br> q(R2R1CK <br><br> o2 <br><br> ,S. <br><br> -(R1 <br><br> q(R2R1C) <br><br> q(R2R1C) <br><br> -/ (R <br><br> NR. <br><br> ^&lt;R,3)m nr4 <br><br> NR. <br><br> N <br><br> ;(R13)m <br><br> ^(R13)m N <br><br> "NR4 <br><br> -(R13)m <br><br> N <br><br> NR. <br><br> 7 (R13)m SO, <br><br> NR. <br><br> / (R13)m <br><br> NR. <br><br> NR. <br><br> j-(R13)m <br><br> "NR. <br><br> "(R13)m <br><br> NR. <br><br> N <br><br> / (R13)m wherein q is an integer from 1 to 2. <br><br> A further embodiment is a compound of formula 5: <br><br> wherein E is selected from the group consisting of: <br><br> "(R13)m <br><br> A <br><br> NR. <br><br> "(R13)m <br><br> NR. <br><br> . ^(R13)m s o2 <br><br> R <br><br> 15- <br><br> (CR1R2)q <br><br> S 02 <br><br> s14 <br><br> 14 <br><br> wherein R is selected from the group consisting of (CrC6)-alkyl, (C3-C7)-cycloalkyl, and (C2-C9)-heterocyclyl, and R15 is selected from the group consisting of hydrogen, (CrC6)-alkyl, (C3-C7)-cycloalkyl, and (C2-C9)-heterocyclyl. <br><br> -19- <br><br> Described herein is a compound of formula 1, wherein R1 is selected from hydrogen, hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8. <br><br> 5 Also described is a compound of formula 1, wherein R1 is -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8. <br><br> Also described is a compound of formula 1 wherein R1 is selected from the group 10 consisting of -(C3-C7)cycloalkyl and -(C2-C9)heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8. <br><br> Also described are compounds of formula 1 wherein R1 is selected from -0(Cr 15 C6)alkyl, -0(C3-C7)cycloalkyl, and -0(C2-C9)heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(C-i-C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8. In a preferred embodiment, R1 is -0(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, 20 hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8. <br><br> One embodiment is a compound of formula 1 wherein R1 is -NR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-25 C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8. <br><br> A further embodiment is a compound of formula 1 wherein R1 is selected from -SR7, -SOR7, -S02R7, and -S02NR5R6, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8. In a 30 preferred embodiment, R1 is -S02NR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(Cr C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8. <br><br> Also described are compounds of formula 1 wherein R1 is -C02R12, -CONR5R6, -35 NHCOR12, -NR12CONR5R6, or -NR12S02R7, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(Cr C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and- <br><br> -20- <br><br> CONR5R8. In a preferred embodiment, R1 is -NR12S02R7, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8. <br><br> 5 Also described is a compound of formula 1 wherein R2 is hydrogen or -(CrC6)alkyl, <br><br> optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, 10 -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups. <br><br> Also described is a compound of formula 1 wherein R2 is -(C3-C7)cycloalkyl, or -(C2-C9)heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, 15 -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups. <br><br> Another embodiment is a compound of formula 1 wherein R2 is -C02R12 and -20 CONR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-25 C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups. <br><br> Also described is a compound of formula 1 wherein R1 is selected from hydrogen, hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is 30 hydrogen or -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and 35 -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups. <br><br> Also described is a compound of formula 1 wherein R1 is selected from hydrogen, hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently <br><br> -21- <br><br> selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and -CONR5R8; and R2 is hydrogen. <br><br> Also described is a compound of formula 1, wherein R1 is -(CrC6)alkyl, optionally 5 substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is hydrogen. <br><br> Also described is a compound of formula 1 wherein R1 is selected from the group consisting of-(C3-C7)cycloalkyl and -(C2-C9)heterocyclyl, optionally substituted by one to three 10 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is hydrogen. <br><br> Also described are compounds of formula 1 wherein R1 is selected from -0(Cr C6)alkyl, -0(C3-C7)cycloalkyl, and -0(C2-C9)heterocyclyl, optionally substituted by one to three 15 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(C-i-C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is hydrogen. <br><br> One embodiment is a compound of formula 1 wherein R1 is -NR5R6 optionally substituted by one to three moieties independently selected from the group consisting of 20 hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is hydrogen. <br><br> A further embodiment is a compound of formula 1 wherein R1 is selected from -SR7, -SOR7, -S02R7, and -S02NR5R6, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, 25 -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is hydrogen. <br><br> Also described are compounds of formula 1 wherein R1 is -C02R12, -CONR5R6, -NHCOR12, -NR12CONR5R6, or -NR12S02R7, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(Cr 30 C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is hydrogen. <br><br> Also described is a compound of formula 1 wherein R2 is hydrogen or -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-35 C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2- <br><br> -22- <br><br> C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; and R1 is hydrogen. <br><br> Also described is a compound of formula 1 wherein R2 is -(C3-C7)cycloalkyl, or -(C2-C9)heterocyclyl, optionally substituted by one to three moieties independently selected from 5 the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; and R1 is 10 hydrogen. <br><br> Another embodiment is a compound of formula 1 wherein R2 is -C02R12 and -CONR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-15 C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; and R1 is hydrogen. <br><br> Also described is a compound of formula 1 wherein R1 is selected from hydrogen, 20 hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and -CONR5R8; and R2 is -(CrC6)alkyl. <br><br> Also described is a compound of formula 1, wherein R1 is -(CrC6)alkyl, optionally 25 substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is -(CrC6)alkyl. <br><br> Also described is a compound of formula 1 wherein R1 is selected from the group consisting of-(C3-C7)cycloalkyl and -(C2-C9)heterocyclyl, optionally substituted by one to three 30 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(C-i-C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is -(CrC6)alkyl. <br><br> Also described are compounds of formula 1 wherein R1 is selected from -0(Cr C6)alkyl, -0(C3-C7)cycloalkyl, and -0(C2-C9)heterocyclyl, optionally substituted by one to three 35 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is -(CrC6)alkyl. <br><br> -23- <br><br> One embodiment is a compound of formula 1 wherein R1 is -NR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is -(CrC6)alkyl. <br><br> 5 A further embodiment is a compound of formula 1 wherein R1 is selected from -SR7, - <br><br> SOR7, -S02R7, and -S02NR5R6, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is -(CrC6)alkyl. <br><br> 10 Also described are compounds of formula 1 wherein R1 is -C02R12, -CONR5R6, - <br><br> NHCOR12, -NR12CONR5R6, or -NR12S02R7, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(Cr C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; and R2 is -(CrC6)alkyl. <br><br> 15 Also described is a compound of formula 1 wherein R2 is hydrogen or -(CrC6)alkyl, <br><br> optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, 20 -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; and R1 is -(CrC6)alkyl. <br><br> Also described is a compound of formula 1 wherein R2 is -(C3-C7)cycloalkyl, or -(C2-C9)heterocyclyl, optionally substituted by one to three moieties independently selected from 25 the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; and R1 is 30 -(C-i-C6)aikyi. <br><br> Another embodiment is a compound of formula 1 wherein R2 is -C02R12 and -CONR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-35 C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2- <br><br> -24- <br><br> C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; and R1 is -(CrC6)alkyl. <br><br> Also described is a compound of formula 1 wherein R1 is selected from hydrogen, hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently 5 selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen or -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-10 C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; and n is 1. <br><br> Also described is a compound of formula 1 wherein R1 is selected from hydrogen, 15 hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(Cr C6)alkyl; and n is 1. <br><br> Also described is a compound of formula 1, wherein R1 is -(CrC6)alkyl, optionally 20 substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 1. <br><br> Also described is a compound of formula 1 wherein R1 is selected from the group consisting of-(C3-C7)cycloalkyl and -(C2-C9)heterocyclyl, optionally substituted by one to three 25 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 1. <br><br> Also described are compounds of formula 1 wherein R1 is selected from -0(Cr C6)alkyl, -0(C3-C7)cycloalkyl, and -0(C2-C9)heterocyclyl, optionally substituted by one to three 30 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(C-i-C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 1. <br><br> One embodiment is a compound of formula 1 wherein R1 is -NR5R6 optionally substituted by one to three moieties independently selected from the group consisting of 35 hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 1. <br><br> -25- <br><br> A further embodiment is a compound of formula 1 wherein R1 is selected from -SR7, -SOR7, -S02R7, and -S02NR5R6, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(Cr 5 C6)alkyl; and n is 1. <br><br> Also described are compounds of formula 1 wherein R1 is -C02R12, -CONR5R6, -NHCOR12, -NR12CONR5R6, or -NR12S02R7, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(Cr C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-10 CONR5R8; R2 is -(CrC6)alkyl; and n is 1. <br><br> Also described is a compound of formula 1 wherein R2 is hydrogen or -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-15 C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is -(Cr C6)alkyl; and n is 1. <br><br> Also described is a compound of formula 1 wherein R2 is -(C3-C7)cycloalkyl, or -(C2-20 C9)heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-25 C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is -(Cr C6)alkyl; and n is 1. <br><br> Another embodiment is a compound of formula 1 wherein R2 is -C02R12 and -CONR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -30 (C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is -(Cr C6)alkyl; and n is 1. <br><br> 35 Also described is a compound of formula 1 wherein R1 is selected from hydrogen, <br><br> hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, <br><br> -26- <br><br> -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(Cr C6)alkyl; and n is 1. <br><br> Also described is a compound of formula 1, wherein R1 is -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of 5 hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 1. <br><br> Also described is a compound of formula 1 wherein R1 is selected from the group consisting of-(C3-C7)cycloalkyl and -(C2-C9)heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -10 CN, -(C-i-C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 1. <br><br> Also described are compounds of formula 1 wherein R1 is selected from -0(Cr C6)alkyl, -0(C3-C7)cycloalkyl, and -0(C2-C9)heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -15 CN, -(C-i-C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 1. <br><br> One embodiment is a compound of formula 1 wherein R1 is -NR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-20 C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 1. <br><br> A further embodiment is a compound of formula 1 wherein R1 is selected from -SR7, -SOR7, -S02R7, and -S02NR5R6, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(Cr 25 C6)alkyl; and n is 1. <br><br> Also described are compounds of formula 1 wherein R1 is -C02R12, -CONR5R6, -NHCOR12, -NR12CONR5R6, or -NR12S02R7, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(Cr C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-30 CONR5R8; R2 is -(CrC6)alkyl; and n is 1. <br><br> Also described is a compound of formula 1 wherein R2 is hydrogen or -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-35 C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2- <br><br> -27- <br><br> C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is -(Cr C6)alkyl; and n is 1. <br><br> Also described is a compound of formula 1 wherein R2 is -(C3-C7)cycloalkyl, or -(C2-C9)heterocyclyl, optionally substituted by one to three moieties independently selected from 5 the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is -(Cr 10 C6)alkyl; and n is 1. <br><br> Another embodiment is a compound of formula 1 wherein R2 is -C02R12 and -CONR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-15 C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is -(Cr C6)alkyl; and n is 1. <br><br> Also described is a compound of formula 1 wherein R1 is selected from hydrogen, 20 hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen or -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, 25 -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; and n is 1. <br><br> 30 Also described is a compound of formula 1 wherein R1 is selected from hydrogen, <br><br> hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 1. <br><br> 35 Also described is a compound of formula 1, wherein R1 is -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of <br><br> -28- <br><br> hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 1. <br><br> Also described is a compound of formula 1 wherein R1 is selected from the group consisting of-(C3-C7)cycloalkyl and -(C2-C9)heterocyclyl, optionally substituted by one to three 5 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 1. <br><br> Also described are compounds of formula 1 wherein R1 is selected from -0(Cr C6)alkyl, -0(C3-C7)cycloalkyl, and -0(C2-C9)heterocyclyl, optionally substituted by one to three 10 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 1. <br><br> One embodiment is a compound of formula 1 wherein R1 is -NR5R6 optionally substituted by one to three moieties independently selected from the group consisting of 15 hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 1. <br><br> A further embodiment is a compound of formula 1 wherein R1 is selected from -SR7, -SOR7, -S02R7, and -S02NR5R6, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, 20 -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 1. <br><br> Also described are compounds of formula 1 wherein R1 is -C02R12, -CONR5R6, -NHCOR12, -NR12CONR5R6, or -NR12S02R7, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(Cr 25 C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 1. <br><br> Also described is a compound of formula 1 wherein R2 is hydrogen or -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-30 C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is hydrogen; and n is 1. <br><br> 35 Also described is a compound of formula 1 wherein R2 is -(C3-C7)cycloalkyl, or -(C2- <br><br> C9)heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, <br><br> -29- <br><br> -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is 5 hydrogen; and n is 1. <br><br> Another embodiment is a compound of formula 1 wherein R2 is -C02R12 and -CONR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-10 C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is hydrogen; and n is 1. <br><br> Also described is a compound of formula 1 wherein R1 is selected from hydrogen, 15 hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen or -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, 20 -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; and n is 2. <br><br> 25 Also described is a compound of formula 1 wherein R1 is selected from hydrogen, <br><br> hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(Cr C6)alkyl; and n is 2. <br><br> 30 Also described is a compound of formula 1, wherein R1 is -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12 -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 2. <br><br> Also described is a compound of formula 1 wherein R1 is selected from the group 35 consisting of -(C3-C7)cycloalkyl and -(C2-C9)heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, - <br><br> -30- <br><br> CN, -(C-i-C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 2. <br><br> Also described are compounds of formula 1 wherein R1 is selected from -0(Cr C6)alkyl, -0(C3-C7)cycloalkyl, and -0(C2-C9)heterocyclyl, optionally substituted by one to three 5 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 2. <br><br> One embodiment is a compound of formula 1 wherein R1 is -NR5R6 optionally substituted by one to three moieties independently selected from the group consisting of 10 hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 2. <br><br> A further embodiment is a compound of formula 1 wherein R1 is selected from -SR7, -SOR7, -S02R7, and -S02NR5R6, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, 15 -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(Cr C6)alkyl; and n is 2. <br><br> Also described are compounds of formula 1 wherein R1 is -C02R12, -CONR5R6, -NHCOR12, -NR12CONR5R6, or -NR12S02R7, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(Cr 20 C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 2. <br><br> Also described is a compound of formula 1 wherein R2 is hydrogen or -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-25 C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is -(Cr C6)alkyl; and n is 2. <br><br> 30 Also described is a compound of formula 1 wherein R2 is -(C3-C7)cycloalkyl, or -(C2- <br><br> C9)heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, 35 -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is -(Cr C6)alkyl; and n is 2. <br><br> -31- <br><br> Another embodiment is a compound of formula 1 wherein R2 is -C02R12 and -CONR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-5 C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is -(Cr C6)alkyl; and n is 2. <br><br> Also described is a compound of formula 1 wherein R1 is selected from hydrogen, 10 hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12 , -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 2. <br><br> Also described is a compound of formula 1, wherein R1 is -(CrC6)alkyl, optionally 15 substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 2. <br><br> Also described is a compound of formula 1 wherein R1 is selected from the group consisting of-(C3-C7)cycloalkyl and -(C2-C9)heterocyclyl, optionally substituted by one to three 20 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 2. <br><br> Also described are compounds of formula 1 wherein R1 is selected from -0(Cr C6)alkyl, -0(C3-C7)cycloalkyl, and -0(C2-C9)heterocyclyl, optionally substituted by one to three 25 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 2. <br><br> One embodiment is a compound of formula 1 wherein R1 is -NR5R6 optionally substituted by one to three moieties independently selected from the group consisting of 30 hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(CrC6)alkyl; and n is 2. <br><br> A further embodiment is a compound of formula 1 wherein R1 is selected from -SR7, -SOR7, -S02R7, and -S02NR5R6, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, 35 -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is -(Cr C6)alkyl; and n is 2. <br><br> -32- <br><br> Also described are compounds of formula 1 wherein R1 is -C02R12, -CONR5R6, -NHCOR12, -NR12CONR5R6, or -NR12S02R7, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(Cr C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-5 CONR5R8; R2 is -(CrC6)alkyl; and n is 2. <br><br> Also described is a compound of formula 1 wherein R2 is hydrogen or -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-10 C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is -(Cr C6)alkyl; and n is 2. <br><br> Also described is a compound of formula 1 wherein R2 is -(C3-C7)cycloalkyl, or -(C2-15 C9)heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-20 C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is -(Cr C6)alkyl; and n is 2. <br><br> Another embodiment is a compound of formula 1 wherein R2 is -C02R12 and -CONR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -25 (C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is -(Cr C6)alkyl; and n is 2. <br><br> 30 Also described is a compound of formula 1 wherein R1 is selected from hydrogen, <br><br> hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen or -(CrC6)alkyl, optionally substituted by one to three moieties independently 35 selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, <br><br> -33- <br><br> -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; and n is 2. <br><br> Also described is a compound of formula 1 wherein R1 is selected from hydrogen, 5 hydroxy, and -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 2. <br><br> Also described is a compound of formula 1, wherein R1 is -(CrC6)alkyl, optionally 10 substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 2. <br><br> Also described is a compound of formula 1 wherein R1 is selected from the group consisting of-(C3-C7)cycloalkyl and -(C2-C9)heterocyclyl, optionally substituted by one to three 15 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(C-i-C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 2. <br><br> Also described are compounds of formula 1 wherein R1 is selected from -0(Cr C6)alkyl, -0(C3-C7)cycloalkyl, and -0(C2-C9)heterocyclyl, optionally substituted by one to three 20 moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 2. <br><br> One embodiment is a compound of formula 1 wherein R1 is -NR5R6 optionally substituted by one to three moieties independently selected from the group consisting of 25 hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 2. <br><br> A further embodiment is a compound of formula 1 wherein R1 is selected from -SR7, -SOR7, -S02R7, and -S02NR5R6, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(CrC6)alkyl, -NR5R6, 30 -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 2. <br><br> Also described are compounds of formula 1 wherein R1 is -C02R12, -CONR5R6, -NHCOR12, -NR12CONR5R6, or -NR12S02R7, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -CN, -(Cr 35 C6)alkyl, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6 and-CONR5R8; R2 is hydrogen; and n is 2. <br><br> -34- <br><br> Also described is a compound of formula 1 wherein R2 is hydrogen or -(CrC6)alkyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-5 C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is hydrogen; and n is 2. <br><br> Also described is a compound of formula 1 wherein R2 is -(C3-C7)cycloalkyl, or -(C2-10 C9)heterocyclyl, optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-15 C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is hydrogen; and n is 2. <br><br> Another embodiment is a compound of formula 1 wherein R2 is -C02R5 and -CONR5R6 optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -20 (C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl R2 moieties may be optionally substituted by one to three R12 groups; R1 is hydrogen; and n is 2. <br><br> 25 Also described is a compound of formula 1 in which R1 and R2 are taken together with the atom(s) to which they are attached to form a -(C3-C10)cycloalkyl optionally substituted by one to three moieties selected from the group consisting of a hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C0)alkenyl, -(C2-C0)alkynyl, -C=N-OH, -C=N-O((C-|-C0)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, 30 -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl moieties of said cyclic group may be optionally substituted by one to three R12 groups. <br><br> Also described is a compound of formula 1 in which R1 and R2 are taken together with the atom(s) to which they are attached to form a -(C2-C9)heterocyclyl optionally substituted by 35 one to three moieties selected from the group consisting of a hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C0)alkenyl, -(C2-C0)alkynyl, -C=N-OH, -C=N-O((C-|-C0)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, <br><br> -35- <br><br> -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl moieties of said cyclic group may be optionally substituted by one to three R12 groups. <br><br> Also described is a compound of formula 1 in which R1 and R2 are taken together with 5 the atom(s) to which they are attached to form a -(C3-C10)cycloalkyl optionally substituted by one to three moieties selected from the group consisting of a hydrogen, halogen, hydroxy, -N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7,wherein said -(C2-10 C6)alkenyl and -(C2-C6)alkynyl moieties of said cyclic group may be optionally substituted by one to three R12 groups; and n is 1. <br><br> Also described is a compound of formula 1 in which R1 and R2 are taken together with the atom(s) to which they are attached to form a -(C2-C9)heterocyclyl optionally substituted by one to three moieties selected from the group consisting of a hydrogen, halogen, hydroxy, -15 N02, -CN, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -C=N-OH, -C=N-0((CrC6)alkyl), -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, -CONR5R6, -CONR5R8, -SR7, -SOR7, -S02R7, -S02NR5R6, -NHCOR12, -NR12CONR5R6, and -NR12S02R7, wherein said -(C2-C6)alkenyl and -(C2-C6)alkynyl moieties of said cyclic group may be optionally substituted by one to three R12 groups; and n is 1. <br><br> 20 In a preferred embodiment, R4 is a substituent selected from the group consisting of hydrogen, (CrC6)alkyl, -(C3-C7)cycloalkyl, and -(C2-C9)heterocyclyl; wherein said (CrC6)alkyl, -(C3-C7)cycloalkyl, and -(C2-C9)heterocyclyl R4 substituents are optionally substituted by one to three moieties independently selected from the group consisting of hydrogen, halogen, hydroxyl, -(CrC6)alkyl, -CN, -NR5R6, -OR12, -(C3-C7)cycloalkyl, -(C2-C9)heterocyclyl, -C02R12, 25 and -CONR5R8; with the proviso that a heteroatom of the foregoing R4 substituents may not be bound to an sp3 carbon atom bound to another heteroatom; and wherein R5 and R8 of said -CONR5R8 group may be taken together with the atoms to which they are attached to form a -(C3-C10)cycloalkyl or -(C2-C9)heterocyclyl. <br><br> In a further preferred embodiment, R4 is hydrogen. <br><br> 30 Also described is a compound of formula 1 wherein R5 and R6 are each substituents independently selected from the group consisting of hydrogen and -(CrC6)alkyl, optionally substituted as described above. <br><br> Specific embodiments are compounds selected from <br><br> N-(1-Methyl-1-phenyl-ethyl)-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-35 trifluoromethyl-pyrimidin-4-ylamino]-methyl}-benzenesulfonamide; <br><br> 3-{[2-(2-Oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-benzenesulfonamide; <br><br> -36- <br><br> 5-{4-[3-(Trifluoro-methanesulfonyl)-benzylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(Piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5 5-{4-[(1-Methanesulfonyl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> N-(3-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 3-Oxo-3-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-10 ylamino]-methyl}-piperidin-1-yl)-propionitrile; <br><br> 5-{4-[3-(1,1-Dioxo-1N6-isothiazolidin-2-yl)-propylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(2-Methyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one; <br><br> 15 5-{4-[(1-Methanesulfonyl-piperidin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> N-{2-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-methanesulfonamide; <br><br> N-{4-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-20 ylamino]-butyl}-methanesulfonamide; <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> N-Methyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-methanesulfonamide; <br><br> 25 Methanesulfonic acid 3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-phenyl ester; <br><br> N-{3-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide; <br><br> 5-{4-[(4-Methanesulfonyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-30 ylamino}-1,3-dihydro-indol-2-one; <br><br> N-(4-Fluoro-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 5-{4-[(5-Oxo-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 35 N-(4-Methoxy-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> -37- <br><br> N-(4-Methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 5-[4-(3-Methanesulfonylmethyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5 5-{4-[(4-Trifluoroacetyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(1-Methanesulfonyl-azetidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> N-Methyl-N-(4-methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-10 pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> N-Methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide; 15 5-{4-[2-(1-Methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(4-Methanesulfonyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> {2,2-Dimethyl-3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-20 4-ylamino]-propyl}-carbamic acid tert-butyl ester; <br><br> 5-[4-(3-lsopropoxy-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(1-Methyl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 25 5-{4-[(Tetrahydro-pyran-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3- <br><br> dihydro-indol-2-one; <br><br> 5-[4-(2-Ethyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one; <br><br> 5-{4-[(Tetrahydro-furan-2R-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-30 1,3-dihydro-indol-2-one; <br><br> 5-{4-[(Tetrahydro-furan-2S-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(5-Methyl-furan-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 35 5-{4-[(1-Methanesulfonyl-pyrrolidin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> -38- <br><br> 5-{4-[(Adamantan-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(Adamantan-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5 5-[4-(2-Methoxy-2-methyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3- <br><br> dihydro-indol-2-one; <br><br> 5-{4-[(endo-Bicyclo[2.2.1]hept-5-en-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> (3-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-10 methyl}-benzyl)-phosphonic acid dimethyl ester; <br><br> 5-[4-(3-Methyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one; <br><br> 5-{4-[(2-Hydroxy-cyclohexylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 15 N-(4-Methoxy-3-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide; <br><br> 5-{4-[(4-Ethanesulfonyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-(4-{[4-(Propane-2-sulfonyl)-morpholin-2-ylmethyl]-amino}-5-trifluoromethyl-20 pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(4-Acetyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(4-Propionyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; 25 5-(4-{[4-(2,2-Dimethyl-propionyl)-morpholin-2-ylmethyl]-amino}-5-trifluoromethyl- <br><br> pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; <br><br> 2-{[2-(2-Oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-morpholine-4-carboxylic acid methyl ester; <br><br> 5-{4-[(4-Methoxyacetyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-30 ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(3-Ethanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(4-Methanesulfonyl-morpholin-2R-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; 35 5-{4-[(4-Methanesulfonyl-morpholin-2S-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> -39- <br><br> indol-2-one; <br><br> 5 N-(4-Fluoro-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin- <br><br> 4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide; <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(4-lsobutyryl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> 10 ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(3,3-Dimethyl-2-oxo-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-[4-(1,2-Dimethyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 15 5-[4-(2-Methoxy-1-methyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3- <br><br> dihydro-indol-2-one; <br><br> 5-{4-[2-(1,1-Dioxo-1D6-isothiazolidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(3-Methylamino-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro- <br><br> 20 indol-2-one; <br><br> 5-{4-[(Pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(6-Methanesulfonyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 25 5-{4-[3-(1,1-Dioxo-1 ,l,6-isothiazolidin-2-yl)-benzylamino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(1R-Phenyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol- <br><br> 2-one; <br><br> 5-(4-lsopropylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; <br><br> 30 5-(4R-sec-Butylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; <br><br> 5-(4S-sec-Butylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; <br><br> 5-[4-(2-Methylamino-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-[4-(1S-Phenyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol- <br><br> 35 2-one; <br><br> 5-{4-[(2-Methanesulfonylmethyl-thiazol-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> -40- <br><br> 5-(4-Propylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; <br><br> 5-[4-(2-Hydroxy-1-methyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-[4-(1-Hydroxymethyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-5 dihydro-indol-2-one; <br><br> 5-{4-[(5-Methanesulfonyl-pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(Pyridin-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 10 5-[4-(1,3-Dimethyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro- <br><br> indol-2-one; <br><br> N-lsopropyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide; <br><br> 5-[4-(1S-Hydroxymethyl-2-methyl-propylamino)-5-trifluoromethyl-pyrimidin-2-15 ylamino]-1,3-dihydro-indol-2-one; <br><br> N-Cyclohexyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide; <br><br> 5-[4-(1,2,3,4-Tetrahydro-naphthalen-1-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; 20 5-{4-[(1-Methanesulfonyl-pyrrolidin-2S-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(3-Methyl-thiophen-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-3R-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-25 ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(2-Hydroxy-1S-phenyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-[4-(2-Hydroxy-1S-methyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 30 5-[4-(1 R-Hydroxymethyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3- <br><br> dihydro-indol-2-one; <br><br> 5-[4-(1-Pyrimidin-4-yl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-[4-(1,1-Dioxo-tetrahydro-1-thiophen-3-ylamino)-5-trifluoromethyl-pyrimidin-2-35 ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(1H-lmidazol-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> -41- <br><br> 5-[4-(2-Piperidin-2-yl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-[4-(lsobutyl-methyl-amino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol- <br><br> 2-one; <br><br> 5 N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin- <br><br> 4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-Ethyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 5-[4-(2-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-10 dihydro-indol-2-one; <br><br> N-lsopropyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 5-{4-[(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; 15 5-{4-[(1-Pyrimidin-2-yl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[2R-(1-Methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[2S-(1-Methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-20 ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(3-Methylsulfanyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-[4-(1S-Hydroxymethyl-3-methylsulfanyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 25 5-[4-(2-Hydroxy-1 R-methyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3- <br><br> dihydro-indol-2-one; <br><br> 5-[4-(1R-Hydroxymethyl-2-methyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> N-Ethyl-N-{3-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-30 ylamino]-propyl}-methanesulfonamide; <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-3R-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(1S-Hydroxymethyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 35 5-[4-(3,5-Dinitro-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro- <br><br> indol-2-one; <br><br> -42- <br><br> N-(2-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-lsopropyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-methanesulfonamide; <br><br> 5 5-[4-(2-Hydroxy-1 -phenyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3- <br><br> dihydro-indol-2-one; <br><br> 5-[4-(1R-Hydroxymethyl-3-methyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-[4-(1S-Hydroxymethyl-3-methyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-10 1,3-dihydro-indol-2-one; <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-2S-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-2R-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; 15 5-[4-(Methyl-pyridin-2-ylmethyl-amino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3- <br><br> dihydro-indol-2-one; <br><br> 5-{4-[(3-Methanesulfonyl-benzyl)-methyl-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> N-Methyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-20 4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 5-[4-(Methyl-pyridin-3-ylmethyl-amino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-3-ylmethyl)-methyl-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; 25 5-[4-(Methyl-pyridin-4-ylmethyl-amino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3- <br><br> dihydro-indol-2-one; <br><br> 5-(4-Cyclopentylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; <br><br> 5-[4-(2,6-Dimethoxy-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 30 5-{4-[(1,5-Dimethyl-1 H-pyrazol-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one and <br><br> 5-[4-(2-lmidazol-1-yl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one. <br><br> Certain preferred embodiments are compounds selected from: 35 5-{4-[(1-Methanesulfonyl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> -43- <br><br> N-Methyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-methanesulfonamide; <br><br> N-Methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide; <br><br> 5 5-{4-[2-(1-Methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(Bicyclo[2.2.1]hept-5-en-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(3-Methyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> 10 one; <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> N-lsopropyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide; 15 N-Cyclohexyl-N-{3-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-propyl}-methanesulfonamide; <br><br> 5-{4-[2-(1-Methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> N-lsopropyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-20 pyrimidin-4-ylamino]-ethyl}-methanesulfonamide; <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-(4-Cyclopentylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; <br><br> Ethanesulfonic acid methyl-{3-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-25 trifluoromethyl-pyrimidin-4-ylamino]-propyl}-amide; <br><br> 2,2,2-Trifluoro-N-methyl-N-{3-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-acetamide; <br><br> N-Methyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-methanesulfonamide; 30 5-(4-Cyclobutylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; <br><br> 5-{4-[2-Hydroxy-2-(1-methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 3-Oxo-3-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propionitrile; 35 5-{4-[(1-Methanesulfonyl-piperidin-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> -44- <br><br> 5-{4-[(4-Methanesulfonyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(5-Oxo-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5 5-{4-[(1-Methanesulfonyl-pyrrolidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(3-lsopropoxy-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(Adamantan-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-10 dihydro-indol-2-one; <br><br> N-{2,2-Dimethyl-3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide; <br><br> 5-{4-[(1-Hydroxy-cyclopentylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 15 5-{4-[(4-Hydroxy-tetrahydro-pyran-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(2-Hydroxy-cyclohexylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(3-Methanesulfonyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-20 dihydro-indol-2-one; <br><br> 5-{4-[(1-Pyrimidin-2-yl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 3-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propionic acid ethyl ester; 25 5-{4-[(1-Ethyl-5-oxo-pyrrolidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 2,N-Dimethyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-butyramide; <br><br> 2-Methoxy-N-methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-30 pyrimidin-4-ylamino]-propyl}-acetamide; <br><br> 5-{4-[2-(1-Acetyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; 35 5-{4-[(1-Methanesulfonyl-pyrrolidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> -45- <br><br> 5-{4-[(1-Pyrimidin-2-yl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 3-{[2-(2-Oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-benzenesulfonamide; <br><br> 5 N-(3-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4- <br><br> ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-(4-Methoxy-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 5-[4-(3-Methanesulfonylmethyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-10 1,3-dihydro-indol-2-one; <br><br> N-Methyl-N-(4-methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 5-{4-[(4-Methanesulfonyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; 15 5-{4-[(5-Methyl-furan-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3- <br><br> dihydro-indol-2-one; <br><br> (3-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-benzyl)-phosphonic acid dimethyl ester; <br><br> 5-{4-[(Pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-20 indol-2-one; <br><br> 5-[5-Trifluoromethyl-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-[4-(3-Ethanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 25 5-{4-[(Pyrimidin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro- <br><br> indol-2-one; <br><br> 5-{4-[(Pyrazin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> N-(4-Fluoro-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-30 4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide; <br><br> 5-{4-[(Pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(6-Methanesulfonyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; 35 5-{4-[(2-Methanesulfonylmethyl-thiazol-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin- <br><br> 2-ylamino}-1,3-dihydro-indol-2-one; <br><br> -46- <br><br> 5-{4-[(5-Methanesulfonyl-pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(3-Methyl-thiophen-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5 5-{4-[(1 H-lmidazol-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3- <br><br> dihydro-indol-2-one; <br><br> N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 5-[4-(2-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-10 dihydro-indol-2-one; <br><br> N-(2-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-Methyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 15 5-{4-[(1,5-Dimethyl-1 H-pyrazol-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(2-lmidazol-1-yl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> N-(5-Methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-20 4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 5-{4-[(3-Methyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 25 5-{4-[(lsochroman-1 -ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3- <br><br> dihydro-indol-2-one; <br><br> 5-{4-[2-(Pyridin-3-yloxy)-propylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[2-(6-Methyl-pyridin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-30 dihydro-indol-2-one; <br><br> 5-{4-[(2,3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[2-(4-Methyl-1H-imidazol-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; 35 5-{4-[2-(1H-Benzoimidazol-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}- <br><br> 1,3-dihydro-indol-2-one; <br><br> -47- <br><br> 5-{4-[(5-Phenyl-4H-[1,2,4]triazol-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(3-Methyl-imidazo[2,1-b]thiazol-6-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5 N-Methyl-N-(2-methyl-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-(2-Methyl-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-(3-Methanesulfonylamino-5-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-10 trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; and <br><br> N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide. <br><br> Preferred embodiments are selected from <br><br> 5-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-15 dihydro-indol-2-one; <br><br> Ethanesulfonic acid methyl-{3-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-amide; <br><br> 5-{4-[(lsochroman-1-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 20 5-{4-[2-(Pyridin-3-yloxy)-propylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3- <br><br> dihydro-indol-2-one; <br><br> 3-{[2-(2-Oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-benzenesulfonamide; <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-25 ylamino}-1,3-dihydro-indol-2-one; <br><br> N-(3-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-Methyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-methanesulfonamide; 30 5-{4-[(4-Methanesulfonyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(3-Methanesulfonylmethyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-35 ylamino}-1,3-dihydro-indol-2-one; <br><br> N-Methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide; <br><br> -48- <br><br> 5-{4-[2-(1-Methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(4-Methanesulfonyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5 5-[4-(3-lsopropoxy-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro- <br><br> indol-2-one; <br><br> 5-{4-[(5-Methyl-furan-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(Bicyclo[2.2.1]hept-5-en-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-10 ylamino}-1,3-dihydro-indol-2-one; <br><br> N-(4-Fluoro-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide; <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; 15 5-{4-[(6-Methanesulfonyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(5-Methanesulfonyl-pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-(2-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-20 dihydro-indol-2-one; <br><br> 5-{4-[(1-Pyrimidin-2-yl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[2-(1-Methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; 25 5-{4-[2-(1-Methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> N-(2-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-30 ylamino}-1,3-dihydro-indol-2-one; <br><br> N-Methyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-Methyl-N-(2-methyl-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; 35 5-[4-(2-Hydroxy-indan-1-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro- <br><br> indol-2-one; <br><br> -49- <br><br> 5-{4-[(1-Hydroxy-cyclopentylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[2-Hydroxy-2-(1-methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; and 5 N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin- <br><br> 4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide. <br><br> Certain specific embodiments include the following componds: <br><br> N-Methyl-N-{3-[({methyl-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-yl]-amino})-methyl]-phenyl}-methanesulfonamide; 10 N-Methyl-N-{4-methyl-3-[({methyl-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5- <br><br> trifluoromethyl-pyrimidin-4-yl]-amino})-methyl]-phenyl}-methanesulfonamide; <br><br> N-(5-Methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-(3-Methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-15 4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-(4-Methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-(2-Methyl-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; 20 5-[4-(3-Methanesulfonyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3- <br><br> dihydro-indol-2-one; <br><br> N-Methyl-N-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-(3-Methanesulfonylamino-5-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-25 trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-Methyl-N-(4-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-Methyl-N-(2-methyl-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; 30 N-Methyl-N-(3-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> 5-{4-[((1S,2R)-2-Hydroxy-cyclohexylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-[4-((1R,2S)-2-Hydroxy-indan-1-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-35 dihydro-indol-2-one; <br><br> 5-[4-((S)-1-Hydroxymethyl-2-phenyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> -50- <br><br> N-(3-(Methanesulfonyl-methyl-amino)-5-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide; <br><br> 5-{4-[(1-Hydroxy-cyclopentylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5 N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin- <br><br> 4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; <br><br> N-(3-Fluoro-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide; <br><br> 5-{4-[2-((S)-1-Methanesulfonyl-pyrrolidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-10 2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[(1-Hydroxy-cyclobutylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 5-{4-[2-((R)-1-Methanesulfonyl-pyrrolidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> 15 N-(2-Fluoro-6-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin- <br><br> 4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide; <br><br> N-(4-Fluoro-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide; <br><br> N-Methyl-N-(4-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-20 4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; <br><br> N-{2,2-Dimethyl-3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-N-methyl-methanesulfonamide; <br><br> N-Methyl-N-(6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; 25 N-(2,4-Difluoro-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide; <br><br> 5-[4-((R)-1-Methanesulfonyl-piperidin-3-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> N-Methyl-N-(6-methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-30 pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(5-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide; <br><br> 5-[4-(1-Methanesulfonyl-piperidin-4-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 35 5-{4-[Methyl-((R)-1-phenyl-ethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3- <br><br> dihydro-indol-2-one; <br><br> 5-(4-Benzylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; <br><br> -51- <br><br> N-(4,6-Dimethyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-N-methyl-methanesulfonamide; <br><br> 5-(4-tert-Butylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; <br><br> 5-[4-((1 R,5S,6S)-3-Methanesulfonyl-3-aza-bicyclo[3.1,0]hex-6-ylamino)-5-5 trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> N-Methyl-N-{3-methyl-3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-butyl}-methanesulfonamide; <br><br> N-(6-Methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; 10 5-{4-[(2-Methanesulfonyl-pyridin-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2- <br><br> ylamino}-1,3-dihydro-indol-2-one; <br><br> 2-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethanesulfonic acid amide; <br><br> N-(3-{Methyl-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-15 yl]-amino}-propyl)-methanesulfonamide; <br><br> N-(2-{Methyl-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-yl]-amino}-ethyl)-methanesulfonamide; <br><br> 5-[4-(2-Methanesulfonylmethyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one; <br><br> 20 2-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]- <br><br> ethanesulfonic acid dimethylamide; <br><br> N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide; <br><br> Ethanesulfonic acid methyl-(2-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-25 trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide; <br><br> Ethanesulfonic acid (2-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide; <br><br> N-Ethyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; 30 N-{1,1-Dimethyl-3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-propyl}-methanesulfonamide; <br><br> N-(5,6-Dimethyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-N-methyl-methanesulfonamide; <br><br> 5-{4-[((R)-4-Methanesulfonyl-morpholin-3-ylmethyl)-amino]-5-trifluoromethyl-35 pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> Propane-1 -sulfonic acid (2-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5- <br><br> trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide; <br><br> -52- <br><br> 5-{4-[2-((R)-4-Methanesulfonyl-morpholin-3-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> Ethanesulfonic acid methyl-(3-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-amide; <br><br> 5 T rifluoro-N-methyl-N-{3-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-propyl}-methanesulfonamide; <br><br> Cyclopropanesulfonic acid methyl-{3-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-amide; <br><br> N-Ethyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-10 ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> Ethanesulfonic acid methyl-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide; <br><br> Ethanesulfonic acid ethyl-(2-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide; <br><br> 15 Ethanesulfonic acid ethyl-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5- <br><br> trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide; <br><br> N-Ethyl-N-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> Ethanesulfonic acid (5-methyl-2-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-20 trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide; <br><br> Ethanesulfonic acid (3-methyl-2-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide; <br><br> Ethanesulfonic acid methyl-(3-methyl-2-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide; 25 2-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]- <br><br> ethanesulfonic acid methylamide; <br><br> Ethanesulfonic acid {3-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-amide; <br><br> C-Methanesulfonyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-30 pyrimidin-4-ylamino]-propyl}-methanesulfonamide; <br><br> Ethanesulfonic acid {2-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-amide; <br><br> C-Methanesulfonyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-methanesulfonamide; 35 N-Methyl-N-(4-methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; <br><br> -53- <br><br> 5-(4-{[1 -(2,2,2-T rifIuoro-acetyl)-piperidin-3-ylmethyI]-amino}-5-trifluoromethyI-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; <br><br> 2,2,2-Trifluoro-ethanesulfonic acid {3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-amide; <br><br> 5 N-Methyl-N-(4-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin- <br><br> 4-ylamino]-methyl}-pyrimidin-2-yl)-methanesulfonamide; <br><br> N-Cyclopropyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide; <br><br> N-Methyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-10 4-ylamino]-methyl}-pyrimidin-4-yl)-methanesulfonamide; <br><br> N-Methyl-N-(6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide; 15 N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin- <br><br> 4-ylamino]-methyl}-pyridin-4-yl)-methanesulfonamide; <br><br> N-Cyclopropyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(6-methyl-3-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-20 pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide; <br><br> 5-{4-[(2-Methanesulfonylmethyl-pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one; <br><br> N-Methyl-N-(4-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide; 25 N-Methyl-N-(3-methyl-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(5-methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(4-methyl-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-30 pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(2-methyl-5-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide; <br><br> N-Methyl-N-(5-methyl-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; 35 N-Methyl-N-(6-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide; <br><br> -54- <br><br> N-Methyl-N-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrimidin-4-yl)-methanesulfonamide; <br><br> N-Methyl-N-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide; <br><br> 5 N-Methyl-N-(4-methyl-2-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide; <br><br> N-Methyl-N-(3-methyl-4-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(5-methyl-4-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-10 pyrimidin-4-ylamino]-methyl}-pyrimidin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(6-methyl-5-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide; <br><br> N-Methyl-N-(6-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrimidin-4-yl)-methanesulfonamide; 15 N-Methyl-N-(5-methyl-4-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(2-methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-4-yl)-methanesulfonamide; <br><br> N-Methyl-N-(6-methyl-4-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-20 pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(5-methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-4-yl)-methanesulfonamide; <br><br> N-Methyl-N-(5-methyl-6-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrimidin-4-yl)-methanesulfonamide; 25 N-Methyl-N-(5-methyl-4-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide; <br><br> N-Methyl-N-(6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrimidin-4-yl)-methanesulfonamide; <br><br> N-Methyl-N-(6-methyl-4-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-30 pyrimidin-4-ylamino]-methyl}-pyrimidin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(2-methyl-4-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide; <br><br> N-Methyl-N-(5-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrimidin-4-yl)-methanesulfonamide; 35 N-Methyl-N-(2-methyl-6-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-pyrimidin-4-yl)-methanesulfonamide; <br><br> -55- <br><br> N-Methyl-N-(6-methyl-4-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide; <br><br> N-Methyl-N-(4-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrimidin-5-yl)-methanesulfonamide; <br><br> 5 N-Methyl-N-(2-methyl-5-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-pyrimidin-4-yl)-methanesulfonamide; <br><br> N-Methyl-N-(4-methyl-6-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrimidin-5-yl)-methanesulfonamide; <br><br> N-Methyl-N-(5-methyl-6-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-10 pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(5-methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide; <br><br> N-Methyl-N-(2-methyl-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrimidin-5-yl)-methanesulfonamide; 15 N-Methyl-N-(3-methyl-6-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl- <br><br> pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide; and <br><br> N-Methyl-N-(6-methyl-5-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrimidin-4-yl)-methanesulfonamide. <br><br> Also described herein is a method for the treatment of abnormal cell growth in a 20 mammal, including a human, comprising administering to said mammal an amount of a compound of the formula 1, as defined above, or a pharmaceutical^ acceptable salt, solvate or prodrug thereof, that is effective in treating abnormal cell growth. In one embodiment of this method, the abnormal cell growth is cancer, including, but not limited to, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular 25 melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of 30 the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers. In one embodiment the 35 method comprises comprising administering to a mammal an amount of a compound of formula 1 that is effective in treating said cancer solid tumor. In one preferred embodiment the solid <br><br> -56- <br><br> tumor is breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, skin (melanoma), endocrine, uterine, testicular, and bladder cancer. <br><br> In another embodiment of said method, said abnormal cell growth is a benign proliferative disease, including, but not limited to, psoriasis, benign prostatic hypertrophy or 5 restinosis. <br><br> Also described is a method for the treatment of abnormal cell growth in a mammal which comprises administering to said mammal an amount of a compound of formula 1, or a pharmaceutical^ acceptable salt, solvate or prodrug thereof, that is effective in treating abnormal cell growth in combination with an anti-tumor agent selected from the group consisting 10 of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens. <br><br> Also described herein is a pharmaceutical composition for the treatment of abnormal cell growth in a mammal, including a human, comprising an amount of a compound of the 15 formula 1, as defined above, or a pharmaceutical^ acceptable salt, solvate or prodrug thereof, that is effective in treating abnormal cell growth, and a pharmaceutical^ acceptable carrier. In one embodiment of said composition, said abnormal cell growth is cancer, including, but not limited to, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, 20 rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft 25 tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers. In another embodiment of said 30 pharmaceutical composition, said abnormal cell growth is a benign proliferative disease, including, but not limited to, psoriasis, benign prostatic hypertrophy or restinosis. <br><br> Also described herein is a method for the treatment of abnormal cell growth in a mammal which comprises administering to said mammal an amount of a compound of formula 1, or a pharmaceutical^ acceptable salt, solvate or prodrug thereof, that is effective in 35 treating abnormal cell growth in combination with another anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, <br><br> -57- <br><br> biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens. The invention also contemplates a pharmaceutical composition for treating abnormal cell growth wherein the composition includes a compound of formula 1, as defined above, or a pharmaceutical^ acceptable salt, solvate or prodrug thereof, that is effective in treating 5 abnormal cell growth, and another anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens. <br><br> Also described is a method for the treatment of a disorder associated with 10 angiogenesis in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula 1, as defined above, or a pharmaceutical^ acceptable salt, solvate or prodrug thereof, that is effective in treating said disorder in combination with one or more anti-tumor agents listed above. Such disorders include cancerous tumors such as melanoma; ocular disorders such as age-related macular degeneration, presumed ocular 15 histoplasmosis syndrome, and retinal neovascularization from proliferative diabetic retinopathy; rheumatoid arthritis; bone loss disorders such as osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, hypercalcemia from tumors metastatic to bone, and osteoporosis induced by glucocorticoid treatment; coronary restenosis; and certain microbial infections including those associated with microbial pathogens selected from adenovirus, 20 hantaviruses, Borrelia burgdorferi, Yersinia spp., Bordetella pertussis, and group A Streptococcus. <br><br> Also described is a method of (and to a pharmaceutical composition for) treating abnormal cell growth in a mammal which comprise an amount of a compound of formula 1, or a pharmaceutical^ acceptable salt, solvate or prodrug thereof, in combination with an amount 25 of one or more substances selected from anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents, which amounts are together effective in treating said abnormal cell growth. <br><br> Anti-angiogenesis agents, such as MMP-2 (matrix-metalloprotienase 2) inhibitors, MMP-9 (matrix-metalloprotienase 9) inhibitors, and COX-II (cyclooxygenase II) inhibitors, can 30 be used in conjunction with a compound of formula 1 in the methods and pharmaceutical compositions described herein. Examples of useful COX-II inhibitors include CELEBREX™ (celecoxib), Bextra (valdecoxib), paracoxib, Vioxx (rofecoxib), and Arcoxia (etoricoxib). Examples of useful matrix metalloproteinase inhibitors are described in WO 96/33172 (published October 24, 1996), WO 96/27583 (published March 7, 1996), European Patent 35 Application No. 97304971.1 (filed July 8, 1997), European Patent Application No. 99308617.2 (filed October 29, 1999), WO 98/07697 (published February 26, 1998), WO 98/03516 (published January 29, 1998), WO 98/34918 (published August 13, 1998), WO 98/34915 <br><br> -58- <br><br> (published August 13, 1998), WO 98/33768 (published August 6, 1998), WO 98/30566 (published July 16, 1998), European Patent Publication 606,046 (published July 13, 1994), European Patent Publication 931,788 (published July 28, 1999), WO 90/05719 (published May 331, 1990), WO 99/52910 (published October 21, 1999), WO 99/52889 (published October 21, 5 1999), WO 99/29667 (published June 17, 1999), PCT International Application No. PCT/IB98/01113 (filed July 21, 1998), European Patent Application No. 99302232.1 (filed March 25, 1999), Great Britain patent application number 9912961.1 (filed June 3, 1999), United States Provisional Application No. 60/148,464 (filed August 12, 1999), United States Patent 5,863,949 (issued January 26, 1999), United States Patent 5,861,510 (issued January 10 19, 1999), and European Patent Publication 780,386 (published June 25, 1997), all of which are herein incorporated by reference in their entirety. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP-2 and/or MMP-9 relative to the other matrix-metalloproteinases (i.e. MMP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13). 15 Some specific examples of MMP inhibitors useful in combination with the compounds described herein are AG-3340, RO 32-3555, RS 13-0830, and the compounds recited in the following list: <br><br> 3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-cyclopentyl)-amino]-propionic acid; <br><br> 20 3-exo-3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1 ]octane-3- <br><br> carboxylic acid hydroxyamide; <br><br> (2R, 3R) 1 -[4-(2-chloro-4-fluoro-benzyloxy)-benzenesulfonyl]-3-hydroxy-3-methyl-piperidine-2-carboxylic acid hydroxyamide; <br><br> 4-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-4-carboxylic acid 25 hydroxyamide; <br><br> 3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-cyclobutyl)-amino]-propionic acid; <br><br> 4-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-4-carboxylic acid hydroxyamide; <br><br> 30 3-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-3-carboxylic acid hydroxyamide; <br><br> (2R, 3R) 1 -[4-(4-fluoro-2-methyl-benzyloxy)-benzenesulfonyl]-3-hydroxy-3-methyl-piperidine-2-carboxylic acid hydroxyamide; <br><br> 3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-1-methyl-ethyl)-35 amino]-propionic acid; <br><br> 3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(4-hydroxycarbamoyl-tetrahydro-pyran-4-yl)-amino]-propionic acid; <br><br> -59- <br><br> 3-exo-3-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1]octane-3-carboxylic acid hydroxyamide; <br><br> 3-endo-3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1]octane-3-carboxylic acid hydroxyamide; and 5 3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-tetrahydro-furan-3-carboxylic acid hydroxyamide; <br><br> and pharmaceutical^ acceptable salts, solvates and prodrugs of said compounds. <br><br> VEGF inhibitors, for example, SU-11248, SU-5416 and SU-6668 (Sugen Inc. of South San Francisco, California, USA), can also be combined with a compound of formula 1. VEGF 10 inhibitors are described in, for example in WO 99/24440 (published May 20, 1999), PCT International Application PCT/IB99/00797 (filed May 3, 1999), in WO 95/21613 (published August 17, 1995), WO 99/61422 (published December 2, 1999), United States Patent 5,834,504 (issued November 10, 1998), WO 98/50356 (published November 12, 1998), United States Patent 5,883,113 (issued March 16, 1999), United States Patent 5,886,020 (issued 15 March 23, 1999), United States Patent 5,792,783 (issued August 11, 1998), U.S. Patent No. US 6,653,308 (issued November 25, 2003), WO 99/10349 (published March 4, 1999), WO 97/32856 (published September 12, 1997), WO 97/22596 (published June 26, 1997), WO 98/54093 (published December 3, 1998), WO 98/02438 (published January 22, 1998), WO 99/16755 (published April 8, 1999), and WO 98/02437 (published January 22, 1998), all of 20 which are herein incorporated by reference in their entirety. Other examples of some specific VEGF inhibitors are IM862 (Cytran Inc. of Kirkland, Washington, USA); Avastin, an anti-VEGF monoclonal antibody of Genentech, Inc. of South San Francisco, California; and angiozyme, a synthetic ribozyme from Ribozyme (Boulder, Colorado) and Chiron (Emeryville, California). <br><br> ErbB2 receptor inhibitors, such as GW-282974 (Glaxo Wellcome pic), and the 25 monoclonal antibodies AR-209 (Aronex Pharmaceuticals Inc. of The Woodlands, Texas, USA) and 2B-1 (Chiron), may be administered in combination with a compound of formula 1. Such erbB2 inhibitors include Herceptin, 2C4, and pertuzumab. Such erbB2 inhibitors include those described in WO 98/02434 (published January 22, 1998), WO 99/35146 (published July 15, 1999), WO 99/35132 (published July 15, 1999), WO 98/02437 (published January 22, 30 1998), WO 97/13760 (published April 17, 1997), WO 95/19970 (published July 27, 1995), United States Patent 5,587,458 (issued December 24, 1996), and United States Patent 5,877,305 (issued March 2, 1999), each of which is herein incorporated by reference in its entirety. ErbB2 receptor inhibitors useful are also described in United States Provisional Application No. 60/117,341, filed January 27, 1999, and in United States Provisional 35 Application No. 60/117,346, filed January 27, 1999, both of which are herein incorporated by reference in their entirety. Other erbb2 receptor inhibitors include TAK-165 (Takeda) and GW-572016 (Glaxo-Wellcome). <br><br> -60- <br><br> Various other compounds, such as styrene derivatives, have also been shown to possess tyrosine kinase inhibitory properties, and some of tyrosine kinase inhibitors have been identified as erbB2 receptor inhibitors. More recently, five European patent publications, namely EP 0 566 226 A1 (published October 20, 1993), EP 0 602 851 A1 (published June 22, 5 1994), EP 0 635 507 A1 (published January 25, 1995), EP 0 635 498 A1 (published January 25, 1995), and EP 0 520 722 A1 (published December 30, 1992), refer to certain bicyclic derivatives, in particular quinazoline derivatives, as possessing anti-cancer properties that result from their tyrosine kinase inhibitory properties. Also, World Patent Application WO 92/20642 (published November 26, 1992), refers to certain bis-mono and bicyclic aryl and 10 heteroaryl compounds as tyrosine kinase inhibitors that are useful in inhibiting abnormal cell proliferation. World Patent Applications W096/16960 (published June 6, 1996), WO 96/09294 (published March 6, 1996), WO 97/30034 (published August 21, 1997), WO 98/02434 (published January 22, 1998), WO 98/02437 (published January 22, 1998), and WO 98/02438 (published January 22, 1998), also refer to substituted bicyclic heteroaromatic 15 derivatives as tyrosine kinase inhibitors that are useful for the same purpose. Other patent applications that refer to anti-cancer compounds are World Patent Application WOOO/44728 (published August 3, 2000), EP 1029853A1 (published August 23, 2000), and W001/98277 (published December 12, 2001) all of which are incorporated herein by reference in their entirety. <br><br> 20 Other antiproliferative agents that may be used with the compounds described herein include inhibitors of the enzyme farnesyl protein transferase and inhibitors of the receptor tyrosine kinase PDGFr, including the compounds disclosed and claimed in the following United States patent applications: 09/221946 (filed December 28, 1998); 09/454058 (filed December 2, 1999); 09/501163 (filed February 9, 2000); 09/539930 (filed March 31, 2000); 25 09/202796 (filed May 22, 1997); 09/384339 (filed August 26, 1999); and 09/383755 (filed August 26, 1999); and the compounds disclosed and claimed in the following United States provisional patent applications: 60/168207 (filed November 30, 1999); 60/170119 (filed December 10, 1999); 60/177718 (filed January 21, 2000); 60/168217 (filed November 30, 1999), and 60/200834 (filed May 1, 2000). Each of the foregoing patent applications and 30 provisional patent applications is herein incorporated by reference in their entirety. <br><br> A compound of formula 1 may also be used with other agents useful in treating abnormal cell growth or cancer, including, but not limited to, agents capable of enhancing antitumor immune responses, such as CTLA4 (cytotoxic lymphocyte antigen 4) antibodies, and other agents capable of blocking CTLA4; and anti-proliferative agents such as other 35 farnesyl protein transferase inhibitors, for example the farnesyl protein transferase inhibitors described in the references cited in the "Background" section, supra. Specific CTLA4 antibodies that can be used include those described in United States Provisional Application <br><br> -61- <br><br> 60/113,647 (filed December 23, 1998) which is herein incorporated by reference in its entirety. <br><br> A compound of formula I may be applied as a sole therapy or may involve one or more other anti-tumor substances, for example those selected from, for example, mitotic 5 inhibitors, for example vinblastine; alkylating agents, for example cis-platin, oxaliplatin, carboplatin and cyclophosphamide; anti-metabolites, for example 5-fluorouracil, capecitabine, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No. 239362 such as N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid; growth factor 10 inhibitors; cell cycle inhibitors; intercalating antibiotics, for example adriamycin and bleomycin; enzymes, for example interferon; and anti-hormones, for example anti-estrogens such as Nolvadex (tamoxifen) or, for example anti-androgens such as Casodex (4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide). <br><br> The compounds may be used alone or in combination with one or more of a variety of 15 anti-cancer agents or supportive care agents. For example, the compounds may be used with cytotoxic agents, e.g., one or more selected from the group consisting of a camptothecin, irinotecan HCI (Camptosar), edotecarin, SU-11248, epirubicin (Ellence), docetaxel (Taxotere), paclitaxel, rituximab (Rituxan) bevacizumab (Avastin), imatinib mesylate (Gleevac), Erbitux, gefitinib (Iressa), and combinations thereof. Also contemplated is the use of the compounds 20 together with hormonal therapy, e.g., exemestane (Aromasin), Lupron, anastrozole (Arimidex), tamoxifen citrate (Nolvadex), Trelstar, and combinations thereof. Described herein is a compound alone or in combination with one or more supportive care products, e.g., a product selected from the group consisting of Filgrastim (Neupogen), ondansetron (Zofran), Fragmin, Procrit, Aloxi, Emend, or combinations thereof. Such conjoint treatment 25 may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. <br><br> The compounds may be used with antitumor agents, alkylating agents, antimetabolites, antibiotics, plant-derived antitumor agents, camptothecin derivatives, tyrosine kinase inhibitors, antibodies, interferons, and/or biological response modifiers. In this regard, 30 the following is a non-limiting list of examples of secondary agents that may be used with the compounds. <br><br> • Alkylating agents include, but are not limited to, nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, melphalan, busulfan, mitobronitol, carboquone, thiotepa, ranimustine, nimustine, temozolomide, AMD-473, altretamine, AP-5280, 35 apaziquone, brostallicin, bendamustine, carmustine, estramustine, fotemustine, <br><br> glufosfamide, ifosfamide, KW-2170, mafosfamide, and mitolactol; platinum- <br><br> -62- <br><br> coordinated alkylating compounds include but are not limited to, cisplatin, carboplatin, eptaplatin, lobaplatin, nedaplatin, oxaliplatin or satrplatin; <br><br> • Antimetabolites include but are not limited to, methotrexate, 6-mercaptopurine riboside, mercaptopurine, 5-fluorouracil (5-FU) alone or in combination with <br><br> 5 leucovorin, tegafur, UFT, doxifluridine, carmofur, cytarabine, cytarabine ocfosfate, <br><br> enocitabine, S-1, gemcitabine, fludarabin, 5-azacitidine, capecitabine, cladribine, clofarabine, decitabine, eflornithine, ethynylcytidine, cytosine arabinoside, hydroxyurea, TS-1, melphalan, nelarabine, nolatrexed, ocfosfate, disodium premetrexed, pentostatin, pelitrexol, raltitrexed, triapine, trimetrexate, vidarabine, <br><br> 10 vincristine, vinorelbine; or for example, one of the preferred anti-metabolites disclosed in European Patent Application No. 239362 such as N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid; <br><br> • Antibiotics include but are not limited to: aclarubicin, actinomycin D, amrubicin, annamycin, bleomycin, daunorubicin, doxorubicin, elsamitrucin, epirubicin, <br><br> 15 galarubicin, idarubicin, mitomycin C, nemorubicin, neocarzinostatin, peplomycin, <br><br> pirarubicin, rebeccamycin, stimalamer, streptozocin, valrubicin or zinostatin; <br><br> • Hormonal therapy agents, e.g., exemestane (Aromasin), Lupron, anastrozole (Arimidex), doxercalciferol, fadrozole, formestane, anti-estrogens such as tamoxifen citrate (Nolvadex) and fulvestrant, Trelstar, toremifene, raloxifene, lasofoxifene, <br><br> 20 letrozole (Femara), or anti-androgens such as bicalutamide, flutamide, mifepristone, <br><br> nilutamide, Casodex® (4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide) and combinations thereof; <br><br> • Plant derived anti-tumor substances include for example those selected from mitotic inhibitors, for example vinblastine, docetaxel (Taxotere) and paclitaxel; <br><br> 25 • Cytotoxic topoisomerase inhibiting agents include one or more agents selected from the group consisting of aclarubicn, amonafide, belotecan, camptothecin, 10-hydroxycamptothecin, 9-aminocamptothecin, diflomotecan, irinotecan HCI (Camptosar), edotecarin, epirubicin (Ellence), etoposide, exatecan, gimatecan, lurtotecan, mitoxantrone, pirarubicin, pixantrone, rubitecan, sobuzoxane, SN-38, <br><br> 30 tafluposide, and topotecan, and combinations thereof; <br><br> • Immunologicals include interferons and numerous other immune enhancing agents. Interferons include interferon alpha, interferon alpha-2a, interferon, alpha-2b, interferon beta, interferon gamma-1a or interferon gamma-n1. Other agents include filgrastim, lentinan, sizofilan, TheraCys, ubenimex, WF-10, aldesleukin, <br><br> 35 alemtuzumab, BAM-002, dacarbazine, daclizumab, denileukin, gemtuzumab ozogamicin, ibritumomab, imiquimod, lenograstim, lentinan, melanoma vaccine (Corixa), molgramostim, OncoVAX-CL, sargramostim, tasonermin, tecleukin, <br><br> -63- <br><br> thymalasin, tositumomab, Virulizin, Z-100, epratuzumab, mitumomab, oregovomab, pemtumomab, Provenge; <br><br> • Biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth, or differentiation of <br><br> 5 tissue cells to direct them to have anti-tumor activity. Such agents include krestin, <br><br> lentinan, sizofiran, picibanil, or ubenimex. <br><br> • Other anticancer agents include alitretinoin, ampligen, atrasentan bexarotene, bortezomib. Bosentan, calcitriol, exisulind, finasteride,fotemustine, ibandronic acid, miltefosine, mitoxantrone, l-asparaginase, procarbazine, dacarbazine, <br><br> 10 hydroxycarbamide, pegaspargase, pentostatin, tazarotne, TLK-286, Velcade, <br><br> Tarceva, or tretinoin; <br><br> • Other anti-angiogenic compounds include acitretin, fenretinide, thalidomide, zoledronic acid, angiostatin, aplidine, cilengtide, combretastatin A-4, endostatin, halofuginone, rebimastat, removab, Revlimid, squalamine, ukrain and Vitaxin; <br><br> 15 • Platinum-coordinated compounds include but are not limited to, cisplatin, carboplatin, <br><br> nedaplatin, or oxaliplatin; <br><br> • Camptothecin derivatives include but are not limited to camptothecin, 10-hydroxycamptothecin, 9-aminocamptothecin, irinotecan, SN-38, edotecarin, and topotecan; <br><br> 20 • Tyrosine kinase inhibitors are Iressa or SU5416; <br><br> • Antibodies include Herceptin, Erbitux, Avastin, or Rituximab; <br><br> • Interferons include interferon alpha, interferon alpha-2a, interferon, alpha-2b, interferon beta, interferon gamma-1a or interferon gamma-n1; <br><br> • Biological response modifiers are agents that modify defense mechanisms of living <br><br> 25 organisms or biological responses, such as survival, growth, or differentiation of tissue cells to direct them to have anti-tumor activity. Such agents include krestin, lentinan, sizofiran, picibanil, or ubenimex; and <br><br> Other antitumor agents include mitoxantrone, l-asparaginase, procarbazine, dacarbazine, hydroxycarbamide, pentostatin, or tretinoin. <br><br> 30 "Abnormal cell growth", as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) that proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; (2) benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation <br><br> 35 occurs; (4) any tumors that proliferate by receptor tyrosine kinases; (5) any tumors that proliferate by aberrant serine/threonine kinase activation; and (6) benign and malignant cells of other proliferative diseases in which aberrant serine/threonine kinase activation occurs.. <br><br> -64- <br><br> The compounds are potent inhibitors of the FAK protein tyrosine kinases, and thus are all adapted to therapeutic use as antiproliferative agents (e.g., anticancer), antitumor (e.g., effective against solid tumors), antiangiogenesis (e.g., stop or prevent proliferationation of blood vessels) in mammals, particularly in humans. In particular, the compounds are 5 useful in the prevention and treatment of a variety of human hyperproliferative disorders such as malignant and benign tumors of the liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblastomas, head and neck, and other hyperplastic conditions such as benign hyperplasia of the skin (e.g.. psoriasis) and benign hyperplasia of the prostate (e.g.. BPH). It is, in 10 addition, expected that the compounds may possess activity against a range of leukemias and lymphoid malignancies. <br><br> In one preferred embodiment cancer is selected from lung cancer, bone cancer, pancreatic cancer, gastric, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, gynecological, rectal cancer, cancer of the anal 15 region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, 20 cancer of the penis, squamous cell, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain, pituitary adenoma, or a combination of one or more of the foregoing cancers. <br><br> 25 In a more preferred embodiment cancer is selected a solid tumor, such as, but not limited to, breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, skin (melanoma), endocrine, uterine, testicular, and bladder. <br><br> The compounds may also be useful in the treatment of additional disorders in which aberrant expression ligand/receptor interactions or activation or signalling events related to 30 various protein tyrosine kinases, are involved. Such disorders may include those of neuronal, glial, astrocytal, hypothalamic, and other glandular, macrophagal, epithelial, stromal, and blastocoelic nature in which aberrant function, expression, activation or signalling of the erbB tyrosine kinases are involved. In addition, the compounds may have therapeutic utility in inflammatory, angiogenic and immunologic disorders involving both identified and as yet 35 unidentified tyrosine kinases that are inhibited by the compounds. <br><br> Described herein are methods for treating or preventing a condition that presents with low bone mass in a mammal (including a human being) which comprise administering to a <br><br> -65- <br><br> mammal in need of such treatment a condition that presents with low bone mass treating amount of a Formula I compound or a pharmaceutically acceptable salt of said compound. <br><br> Also described are methods wherein the condition that presents with low bone mass is osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, 5 alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, periodontitis or prosthetic ingrowth. <br><br> Also described are methods for treating osteoporosis in a mammal (including a human being) which comprise administering to a mammal in need of such treatment an osteoporosis treating amount of a Formula I compound or a pharmaceutically acceptable salt 10 of said compound. <br><br> Also described are methods for treating a bone fracture or an osteoporotic fracture in a mammal which comprise administering to a mammal in need of such treatment a bone fracture treating or an osteoporotic fracture treating amount of a Formula I compound or a pharmaceutically acceptable salt of said compound. <br><br> 15 The term "osteoporosis" includes primary osteoporosis, such as senile, <br><br> postmenopausal and juvenile osteoporosis, as well as secondary osteoporosis, such as osteoporosis due to hyperthyroidism or Cushing syndrome (due to corticosteroid use), acromegaly, hypogonadism, dysosteogenesis and hypophospatasemia. <br><br> The term "treating", as used herein, unless otherwise indicated, means reversing, 20 alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above. <br><br> Also described is a pharmaceutical composition comprising a compound of formula 25 (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier. <br><br> Also described is a process for the preparation of a pharmaceutical composition which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent 30 or carrier. <br><br> For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of formula (l)/salt/solvate (active ingredient) may be in the range from 1 mg to 1 gram, preferably 1 mg to 250 mg, more 35 preferably 10 mg to 100 mg. <br><br> Also described are sustained release compositions. <br><br> -66- <br><br> In one aspect, the invention provides a pharmaceutically acceptable salt of N-methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide. <br><br> In another aspect, the invention provides a pharmaceutical composition comprising a 5 pharmaceutically acceptable carrier and N-methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide or a pharmaceutically acceptable salt thereof. <br><br> In another aspect, the invention provides a use of N-methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-10 methanesulfonamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer in a mammal. <br><br> Detailed Description of the Invention In the description in this specification reference may be made to subject matter that is 15 not within the scope of the claims of the current application. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the claims of this application. <br><br> The term "comprising" as used in this specification means "consisting at least in part of". When interpreting each statement in this specification that includes the term 20 "comprising", features other than that or those prefaced by the term may also be present. Related terms such as "comprise" and "comprises" are to be interpreted in the same manner. <br><br> The compounds of formula 1 can be prepared using the synthetic route outlined in Scheme 1. The substituents in Scheme 1 have the same meaning as the substituents defined for formula 1. <br><br> 8 <br><br> H <br><br> R4'N"(CR1R2)nR3 <br><br> 9 <br><br> Scheme 1 <br><br> -67- <br><br> Compounds of formula 1 can be prepared starting from the 5-amino-oxindole (6) and pyrimidine (7). Combining 7 with a Lewis Acid at temperatures ranging from -15 to 45°C for a time period of 10-60 minutes in an inert solvent (or solvent mixture) followed by addition of 6 and a suitable base provides after the period of 1-24 h the intermediate 4-chloropyrimidine (8) 5 in high yields. Examples of inert solvents include but are not limited to THF, 1,4-dioxane, n-BuOH, i-PrOH, dichloromethane and 1,2-dichloroethane. Examples of suitable bases employed may include but are not limited to (i) non-nucleophilic organic bases for example triethylamine or diisopropylethylamine (ii) inorganic bases such as potassium carbonate or cesium carbonate or (iii) resin bound bases such as MP-carbonate. <br><br> 10 Examples of Lewis Acids include but are not limited to halide salts of magnesium, <br><br> copper, zinc, tin or titanium. In the next reaction, intermediate 8 is reacted with an amine of the formula 9 either neat or in the presence of an inert solvent (or solvent mixture) at temperatures ranging from 0 to 150°C to provide the compounds of formula 1. Optionally this reaction can be run in the presence of a suitable base. Examples of suitable solvents for this <br><br> 15 reaction include but are not limited to THF, 1,4-dioxane, DMF, N-methyl-pyrrolidinone, EtOH, n-BuOH, i-PrOH, dichloromethane, 1,2-dichloroethane, DMSO or acetonitrile. Suitable bases are as outlined above. <br><br> Compounds described herein may be synthetically transformed into other compounds by techniques known to those skilled in the art. Simply for illustrative purposes and without <br><br> 20 limitation, such methods include: <br><br> a) removal of a protecting group by methods outlined in T. W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", Second Edition, John Wiley and Sons, New York, 1991; e.g., emoval of a BOC protecting group with an acid source such as HCI or trifluoroacetic acid. <br><br> 25 b) displacement of a leaving group (halide, mesylate, tosylate, etc) with functional groups such as but not limited to a primary or secondary amine, thiol or alcohol to form a secondary or tertiary amine, thioether or ether, respectively. <br><br> c) treatment of phenyl (or substituted phenyl) carbamates with primary of secondary amines to form the corresponding ureas as in Thavonekham, B et. al. Synthesis (1997), 1_0, <br><br> 30 p1189; <br><br> d) reduction of propargyl or homopropargyl alcohols or N-BOC protected primary amines to the corresponding E-allylic or E-homoallylic derivatives by treatment with sodium bis(2-methoxyethoxy)aluminum hydride (Red-AI) as in Denmark, S. E.; Jones, T. K. J. Org. Chem. (1982) 47, 4595-4597 or van Benthem, R. A. T. M.; Michels, J. J.; Speckamp, W. N. <br><br> 35 Synlett (1994), 368-370; <br><br> e) reduction of alkynes to the corresponding Z-alkene derivatives by treatment hydrogen gas and a Pd catalyst as in Tomassy, B. et. al. Synth. Commun. (1998), 28, p1201 <br><br> -68- <br><br> f) treatment of primary and secondary amines with an isocyanate, acid chloride (or other activated carboxylic acid derivative), alkyl/aryl chloroformate or sulfonyl chloride to provide the corresponding urea, amide, carbamate or sulfonamide; <br><br> g) reductive amination of a primary or secondary amine using an aldehyde or ketone and an appropriate reducing reagent. <br><br> h) treatment of alcohols with an isocyanate, acid chloride (or other activated carboxylic acid derivative), alkyl/aryl chloroformate or sulfonyl chloride to provide the corresponding carbamate, ester, carbonate or sulfonic acid ester. <br><br> Amines of the formula 9 may be purchased and used directly or alternatively be prepared by one skilled in the art using ordinary chemical transformations. For example; arylalkylamines or heteroarylalkylamines may be prepared from the corresponding nitrile by catalytic hydrogenation using catalysts such as Pd/C or Raney Nickel or by lithium aluminum hydride reduction, (see Rylander, Catalytic Hydrogenation in Organic Synthesis, Academic Press, 1979). <br><br> nh2 ch3 <br><br> Ho/ Pd on Carbon L ^ N <br><br> S02CH3 ► 111 "s°2CH3 <br><br> Inert Solvent [I J <br><br> The nitrile starting materials can be either purchased or prepared from the corresponding aryl/heteroaryl bromide, iodide or triflate and Zn(CN)2 using Pd coupling conditions found in Tschaen, D. M., et. al Synthetic Communications (1994), 24, 6, pp 887-890. <br><br> Br\ ,SO?CH <br><br> '2°m3 Zn(CN)2/ Pd NC^ /S02CH <br><br> Inert Solvent <br><br> Alternatively, benzylamines or heteroarylmethylamines can be prepared by reacting the appropriate arylalkyl or heteroarylalkyl halide and the potassium salt of (BOC)2NH (reference) and subsequent removal of the BOC groups with acid. <br><br> CI Boc^ ^Boc Bocx^,Boc ch3 h Base f ch <br><br> Inert Solvent n02 <br><br> Amines, protected forms of amines, precursors to amines and precursors to the protected forms of amines of formula 9 can be prepared by combining the appropriate alkyne, or alkenyl stannane, alkenyl borane, alkenyl boronic acid, boronic ester with the appropriate aryl or heteroaryl bromide, iodide or triflate using Pd coupling conditions as found in Tsuji, J.; Palladium Reagents and Catalysis, John Wiley and Sons 1999 and references cited therein. <br><br> -69- <br><br> Appropriately protected amines of formula 9 may be converted to different amines of formula 9 according to methods familiar to those skilled in the art for exampleas but limited to: 5 (a) oxidation of a thioether to a sulfoxide or sulfone. <br><br> HhTB°C 300 <br><br> MCPBA <br><br> Inert Solvent <br><br> (b) N-alkylation of a sulfanilide can be achieved under phase transfer using conditions described by Brehme, R. "Synthesis", (1976), pp113-114. <br><br> Inert Solvent <br><br> 10 As understood by those skilled in the art, the chemical transformation to convert an aryl halide or triflate or heteroaryl halide or triflate to an aromatic or heteroaromatic amine may be carried out using conditions currently outlined in the literature, see Hartwig, J. F.: "Angew. Chem. Int. Ed." (1998), 37, pp. 2046-2067, Wolfe, J. P.; Wagaw, S.; Marcoux, J. F.; Buchwald, S.L.; "Acc. Chem. Res.", (1998), 31, pp 805-818, Wolfe, J. P.; Buchwald, S.L.; "J. 15 Org. Chem.", (2000), 65, pp 1144-1157, Muci, A. R.; Buchwald, S. L.; "Topics in Current Chemistry" (2002), pp131-209 and references cited therein. Further, as understood by those skilled in the art, these same aryl or heteroaryl aminatiion chemical transformations may alternatively be carried out on nitrile (or primary amide) precursors which provide amines of the formula 5 after nitrile (or amide) reduction. Protected amines of formula 5 may be 20 further converted to different amines of formula 5 according to methods familiar to those skilled in the art. <br><br> NH <br><br> NC^ ^Br if^^Y <br><br> pd <br><br> Inert Solvent <br><br> The in vitro activity of the compounds of formula 1_ may be determined by the following procedure. More particularly, the following assay provides a method to determine 25 whether compounds of the formula 1_ inhibit the tyrosine kinase activity of the catalytic <br><br> -70- <br><br> construct FAK(410-689). The assay is an ELISA-based format, measuring the inhibition of poly-glu-tyr phosphorylation by FAK(410-689). <br><br> The assay protocol has three parts: <br><br> I. Purification and cleavage of His-FAK(410-689) 5 II. FAK410-689 (a.k.a. FAKcd) Activation <br><br> III. FAKcd Kinase ELISA Materials: <br><br> -Ni-NTA agarose (Qiagen) <br><br> -XK-16 column (Amersham-Pharmacia) <br><br> 10 -300 mM Imidizole <br><br> -Superdex 200 HiLoad 16/60 prep grade column (Amersham Biotech.) <br><br> -Antibody: Anti-Phosphotyrosine HRP-Conjugated Py20 (Transduction labs). <br><br> -FAKcd: Purified and activated in house <br><br> -TMB Microwell Peroxidase Substrate (Oncogene Research Products #CL07) 15 -BSA: Sigma #A3294 <br><br> -Tween-20: Sigma #P1379 -DMSO: Sigma #D-5879 -D-PBS: Gibco #14190-037. <br><br> Reagents for Purification: <br><br> 20 -Buffer A: 50mM HEPES pH 7.0, <br><br> 500mM NaCI, <br><br> 0.1 mM TCEP <br><br> CompleteTM protease inhibitor cocktail tablets (Roche) <br><br> -Buffer B: 25mM HEPES pH 7.0, <br><br> 25 400mM NaCI <br><br> 0.1mM TCEP. <br><br> -Buffer C: 10mM HEPES pH 7.5, <br><br> 200mM Ammonium Sulfate 0.1mM TCEP. <br><br> 30 Reagents for Activation <br><br> -FAK(410-689): 3 tubes of frozen aliquots at 150ul/tube for a total of 450ul at 1.48 mg/ml (660ug) <br><br> -His-Src(249-524): -0.74 mg/ml stock in 10mM HEPES, 200mM (NH4)2S04 -Src reaction buffer (Upstate Biotech): <br><br> 35 100 mM Tris-HCI pH7.2, <br><br> 125mM MgCI2, <br><br> 25 mM MnCI2, <br><br> -71- <br><br> 2mM EDTA, <br><br> 250 uM Na3V04, <br><br> 2 mM DTT -Mn2+/ATP cocktail (Upstate Biotech) <br><br> 5 75mM MnCI2 <br><br> 500 uM ATP 20mM MOPS pH 7.2 1 mM Na3V04 <br><br> 25mM -glycerol phosphate 10 5mM EGTA <br><br> 1 mM DTT -ATP: 150mM stock -MgCI2: 1 M Stock -DTT: 1M stock 15 Reagents for FAKcd Kinase ELISA -Phosphorylation Buffer: <br><br> 50mM HEPES, pH 7.5, <br><br> 125mM NaCI, <br><br> 48mM MgCI2 20 -Wash Buffer: TBS + 0.1% Tween-20. <br><br> -Blocking Buffer: <br><br> Tris Buffer Saline, <br><br> 3% BSA, <br><br> 0.05% Tween-20, filtered. <br><br> 25 -Plate Coating Buffer: <br><br> 50mg/ml Poly-Glu-Tyr (Sigma #P0275) in Phosphate buffer Saline (DPBS). -ATP: 0.1 M ATP in H20 or HEPES, pH7. <br><br> Note: ATP Assay Buffer: <br><br> Make up as 75 uM ATP in PBS, so that 80 ul in 30 120 ul reaction volume=50uM final ATP concentration. <br><br> I. Purification of His-FAKcd(410-689) <br><br> 1. Resuspend 130 g baculovirus cell paste containing the over expressed His-FAKcd410-689 recombinant protein in 3 volumes (400ml) of Buffer A, <br><br> 2. Lyse cells with one pass on a microfluidizer <br><br> 35 3. Remove cell debris by centrifugation at 40C for 35 minutes at 14,000 rpm in a Sorval SLA-1500 rotor. <br><br> -72- <br><br> 4. Transfer the supernatant to a clean tube and add 6.0 ml of Ni-NTA agarose (Qiagen) <br><br> 5. Incubate the suspension with gentle rocking at 40C for 1 hour <br><br> 6. Centrifuge suspension at 700 x g in a swinging bucket rotor. <br><br> 5 7. Discard the supernatant and resuspend the agarose beads in 20.0 ml of <br><br> Buffer A <br><br> 8. Transfer the beads to an XK-16 column (Amersham-Pharmacia) connected toaFPLCTM. <br><br> 9. Wash the agarose-beads with 5 column volumes of Buffer A and elute off the <br><br> 10 column with a step gradient of Buffer A containing 300mM Imidizole. <br><br> 10. Perform a buffer exchange of the eluted fractions into Buffer B <br><br> 11. Following buffer exchange, pool the fractions and add thrombin at a 1:300 (w/w) ratio and incubated overnight at 13°C to remove the N-terminal His-tag (His-FAK410-698 -&gt; FAK410-689 (a.k.a. FAKcd)). <br><br> 15 12. Add the reaction mixture back onto the Ni-NTA column equilibrated with <br><br> Buffer A and collect the flow-through. <br><br> 13. Concentrate the flow-through down to 1.7 ml and load directly onto a Superdex 200 HiLoad 16/60 prep grade column equilibrated with Buffer C. The desired protein elutes between 85 - 95 ml. <br><br> 20 14. Aliquot the FAKcd protein and store frozen at -80°C <br><br> II. FAK activation <br><br> 1. To 450ul of FAK(410-689) at 1.48 mg/ml (660ug) add the following: <br><br> 30ul of 0.037 mg/ml (1 uM) His-Src(249-524) <br><br> 30ul of 7.5 mM ATP <br><br> 25 12ul of 20 mM MgCI2 <br><br> 10ul Mn2+/ATP cocktail (UpState Biotech.) <br><br> 4ul of 6.7mM DTT <br><br> 60ul Src Reaction Buffer (UpState Biotech.) <br><br> 2. Incubate Reaction for at least 3 hours at room temperature <br><br> 30 At time t0, almost all of the FAK(410-689) is singly phosphorylated. The second phosphorylation is slow. Att12o (t = 120 minutes), add 10ul of 150 mM ATP. <br><br> T0 = (Start) 90% singly phosphorylated FAK(410-689) (1 P04) <br><br> T43 = (43 min) 65% singly phosphorylated (1 P04), 35% doubly phosphorylated (2 <br><br> P04) <br><br> 35 Tgo = (90 min) 45% 1 P04, 55% 2 P04 <br><br> T150 = 15% 1 P04, 85% 2 P04 <br><br> T2io = &lt;10% 1 P04, &gt;90% 2 P04 desalted sample <br><br> -73- <br><br> 3. Add 180 ul aliquots of the desalted material to NiNTA spin column and incubate on spin column <br><br> 4. Spin at 10k rpm (microfuge), for 5 min to isolate and collect flow through (Activated FAK(410-689)) and remove His-Src (captured on column) <br><br> 5 III. FAKcd Kinase ELISA <br><br> 1. Coat 96-well Nunc MaxiSorp plates with poly-glu-tyr (pGT) at 10 ug/well: Prepare 10 ug/ml of pGT in PBS and aliquot 100 ul/well. Incubate the plates at 37°C overnight, aspirate the supernatant, wash the plates 3 times with Wash Buffer, and flick to dry before storing at 4°C. <br><br> 10 2. Prepare compound stock solutions of 2.5 mM in 100% DMSO. The stocks are subsequently diluted to 60X of the final concentration in 100% DMSO, and diluted 1:5 in Kinase Phosphorylation Buffer. <br><br> 3. Prepare a 75 uM working ATP solution in Kinase phosphorylation buffer. Add 80 ul to each well for a final ATP concentration of 50 uM. <br><br> 15 4. Transfer 10 ul of the diluted compounds (0.5log serial dilutions) to each well of the pGT assay plate, running each compound in triplicates on the same plate. <br><br> 5. Dilute on ice, FAKcd protein to 1:1000 in Kinase Phosphorylation Buffer. Dispense 30 ul per well. <br><br> 6. Note: Linearity and the appropriate dilution must be pre-determined for each <br><br> 20 batch of protein. The enzyme concentration selected should be such that quantitation of the assay signal will be approximately 0.8-1.0 at OD450, and in the linear range of the reaction rate. <br><br> 7. Prepare both a No ATP control (noise) and a No Compound Control (Signal): <br><br> 8. (Noise) One blank row of wells receives 10 ul of 1:5 diluted compounds in <br><br> 25 DMSO, 80ul of Phosphorylation buffer (minus ATP), and 30 ul FAKcd solution. <br><br> 9. (Siganl) Control wells receive 10 ul of 1:5 diluted DMSO (minus Compound) in Kinase phosphorylation buffer, 80 ul of 75 uM ATP, and 30 ul of 1:1000 FAKcd enzyme. <br><br> 10. Incubate reaction at room temperature for 15 minutes with gentle shaking on a plate shaker. <br><br> 30 11. Terminate the reaction by aspirating off the reaction mixture and washing 3 <br><br> times with wash buffer. <br><br> 12. Dilute phospho-tyrosine HRP-conjugated (pY20HRP) antibody to 0.250ug/ml (1:1000 of Stock) in blocking buffer. Dispense 100 ul per well, and incubate with shaking for 30min. at R.T. <br><br> 35 13. Aspirate the supernatant and wash the plate 3 times with wash buffer. <br><br> -74- <br><br> 14. Add 100 ul per well of room temperature TMB solution to initiate color development. Color development is terminated after approximately 15-30 sec. by the addition of 10Oul of 0.09M H2S04 per well. <br><br> 15. The signal is quantitated by measurement of absorbance at 450nm on the 5 BioRad microplate reader or a microplate reader capable of reading at OD450. <br><br> 16. Inhibition of tyrosine kinase activity would result in a reduced absorbance signal. The signal is typically 0.8-1.0 OD units. The values are reported as IC50s, uM concentration. <br><br> FAK Inducible cell-based ELISA: Final Protocol <br><br> 10 Materials: <br><br> Reacti-Bind Goat Anti-Rabbit Plates 96-well (Pierce Product#15135ZZ @115.00 <br><br> USD) <br><br> FAKpY397 rabbit polyclonal antibody (Biosource #44624 @315.00 USD) <br><br> ChromePure Rabbit IgG, whole molecule (Jackson Laboratories #001-000-003 15 @60/25mg USD) <br><br> UBI aFAK clone 2A7 mouse monoclonal antibody (Upstate#05-182 @ 289.00 USD) Peroxidase-conjugated AffiniPure Goat Anti-Mouse IgG (Jackson Labs #115-035-146 @95/1.5ml USD) <br><br> SuperBlock TBS (Pierce Product#37535ZZ @99 USD) <br><br> 20 Bovine Serum Albumin (Sigma #A-9647 @117.95/100 g USD) <br><br> TMB Peroxidase substrate (Oncogene Research Products #CL07-100ml @40.00 <br><br> USD) <br><br> Na3V04 Sodium Orthovanadate (Sigma #S6508 @43.95/50g USD) <br><br> MTT substrate (Sigma # M-2128 @25.95/500mg USD) <br><br> 25 Growth Media: DMEM+10%FBS, P/S, Glu, 750 ug/ml Zeocin and 50 ug/ml <br><br> Hygromycin (Zeocin InVitrogen #R250-05 @ 725 USD and Hygromycon InVitrogen #R220-05 @ 150 USD) <br><br> Mifepristone InVitrogen # H110-01 @ 125 USD <br><br> CompleteTM EDTA-free Protease Inhibitor pellet Boehringer Mannheim #1873580 30 FAK cell-based Protocol for selectivity of kinase-dependent phosphoFAKY397 <br><br> Procedure: <br><br> An inducible FAK cell-based assay in ELISA format for the screening of chemical matter to identify tyrosine kinase specific inhibitors was developed. The cell-based assay exploits the mechanism of the GeneSwitchTM system (InVitrogen) to exogenously control the 35 expression and phosphorylation of FAK and the kinase-dependent autophosphorylation site at residue Y397. <br><br> -75- <br><br> Inhibition of the kinase-dependent autophosphorylation at Y397 results in a reduced absorbance signal at OD450. The signal is typically 0.9 to 1.5 OD450 units with the noise falling in the range of 0.08 to 0.1 OD450 units. The values are reported as IC50s, uM concentration. <br><br> 5 On day 1, grow A431»FAKwt in T175 flasks. On the day prior to running the FAK <br><br> cell-assay, seed A431»FAKwt cells in growth media on 96-well U-bottom plates. Allow cells to sit at 37oC, 5% C02 for 6 to 8 hours prior to FAK induction. Prepare Mifepristone stock solution of 10 uM in 100 % Ethanol. The stock solution is subsequently diluted to 10 X of the final concentration in Growth Media. Transfer 10 ul of this dilution (final concentration of 0.1 10 nM Mifepristone) into each well. Allow cells to sit at 37oC, 5% C02 overnight (12 to 16 hours). Also, prepare control wells without Mifepristone induction of FAK expression and phosphorylation. <br><br> On day 2, coat Goat Anti-Rabbit plate(s) with 3.5 ug/ml of phosphospecific FAKpY397 polyclonal antibody prepared in SuperBlock TBS buffer, and allow plate(s) to shake on a plate 15 shaker at room temperature for 2 hours. Optionally, control wells may be coated with 3.5 ug/ml of control Capture antibody (Whole Rabbit IgG molecules) prepared in SuperBlock TBS. Wash off excess FAKpY397 antibody 3 times using buffer. Block Anti-FAKpY397 coated plate(s) with 200 ul per well of 3%BSA/0.5%Tween Blocking buffer for 1 hour at room temperature on the plate shaker. While the plate(s) are blocking, prepare compound stock 20 solutions of 5 mM in 100 % DMSO. The stock solutions are subsequently serially diluted to 100X of the final concentration in 100% DMSO. Make a 1:10 dilution using the 100X solution into growth media and transfer 10 ul of the appropriate compound dilutions to each well containing either the FAK induced or uninduced control A431 cells for 30 minutes at 37oC, 5% C02. Prepare RIPA lysis buffer (50 mM Tris-HCI, pH7.4, 1% NP-40, 0.25% Na-25 deoxycholate, 150 mM NaCI, 1 mM EDTA, 1 mM Na3V04, 1 mM NaF, and one CompleteTM EDTA-free protease inhibitor pellet per 50 ml solution). At the end of 30 minutes compound treatment, wash off compound 3 times using TBS-T wash buffer. Lyse cells with 100 ul/well of RIPA buffer. <br><br> To the coated plate, remove blocking buffer and wash 3 times using TBS-T wash 30 buffer. Using a 96-well automated microdispenser, transfer 100 ul of whole cell-lysate (from step 6) to the Goat Anti-Rabbit FAKpY397 coated plate(s) to capture phosphoFAKY397 proteins. Shake at room temperature for 2 hours. Wash off unbound proteins 3 times using TBS-T wash buffer. Prepare 0.5 ug/ml (1:2000 dilution) of UBI aFAK detection antibody in 3%BSA/0.5% Tween blocking buffer. Dispense 100 ul of UBI aFAK solution per well and 35 shake for 30 minutes at room temperature. Wash off excess UBI aFAK antibody 3 times using TBS-T wash buffer. Prepare 0.08 ug/ml (1:5000 dilution) of secondary Anti-Mouse Peroxidase (Anti-2MHRP) conjugated antibody. Dispense 100 ul per well of the Anti-2MHRP <br><br> -76- <br><br> solution and shake for 30 minutes at room temperature. Wash off excess Anti-2MHRP antibody 3 times using TBS-T wash buffer. Add 100 ul per well of room temperature TMB substrate solution to allow for color development. Terminate the TMB reaction with 100 ul per well of TMB stop solution (0.09M H2S04) and quantitate the signal by measurement of 5 absorbance at 450 nm on the BioRad microplate reader. <br><br> Additional FAK cell assays are hereby incorporated by reference from Pfizer Attorney Docket No. PC11699 entitled "INDUCIBLE FOCAL ADHESION KINASE CELL ASSAY". <br><br> In a preferred embodiment, the compounds have an in vitro activity as determined by a kinase assay, e.g., such as that described herein, of less than 500 nM. Preferably, the 10 compounds have an IC50 of less than 25 nM in the kinase assay, and more preferably less than 10 nM. In a further preferred embodiment, the compounds exhibit an IC50 in a FAK cell based assay, e.g., such as that described herein, of less than 1 jaM, more preferably less than 100 nM, and most preferably less than 25 nM. <br><br> Still further, the following assay(s) may be used to assess the ability of a compound 15 to inhibit osteoporosis and/or low bone mass, as described above. <br><br> (1) Effect of Test Compound on Body Weight, Body Composition and Bone Density in the Aged Intact and Ovariectomized Female Rat <br><br> This assay may be used to test the effects of a test compound in aged intact or 20 ovariectomized (OVX) female rat model. <br><br> Study Protocol <br><br> Sprague-Dawley female rats are sham-operated or OVX at 18 months of age, while a group of rats is necropsied at day 0 to serve as baseline controls. One day post-surgery, the rats are treated with either vehicle or test compound. The vehicle or test compound is 25 administered twice a week (Tuesday and Friday) by subcutaneous injection (s.c.), with the test compound being administered at an average dose of 10 milligrams per kilogram of body weight per day (10 mg/kg/day). <br><br> All rats are given s.c. injection of 10 mg/kg of calcein (Sigma, St.Louis, MO) for fluorescent bone label 2 and 12 days before necropsy. On the day of necropsy, all rats under 30 ketamine/xylazine anesthesia are weighed and undergoe dual-energy X-ray absorptiometry (DXA, QDR-4500/W, Hologic Inc., Waltham, MA) equipped with Rat Whole Body Scan software for lean and fat body mass determination. The rats are necropsied, then autopsied and blood is obtained by cardiac puncture. The distal femoral metaphysis and femoral shafts from each rat are analyzed by peripheral quantitative computerized tomography (pQCT), and 35 volumetric total, trabecular and cortical bone mineral content and density are determined. <br><br> Peripheral Quantitative Computerized Tomography (pQCT) Analysis: Excised femurs are scanned by a pQCT X-ray machine (Stratec XCT Research M, Norland Medical Systems, <br><br> -77- <br><br> Fort Atkinson, Wl.) with software version 5.40. A 1 millimeter (mm) thick cross section of the femur metaphysis is taken at 5.0 mm (proximal femoral metaphysis, a primary cancellous bone site) and 13 mm (femoral shafts, a cortical bone site) proximal from the distal end with a voxel size of 0.10 mm. Cortical bone is defined and analyzed using contour mode 2 and 5 cortical mode 4. An outer threshold setting of 340 mg/cm3 is used to distinguish the cortical shell from soft tissue and an inner threshold of 529 mg/cm3 to distinguish cortical bone along the endocortical surface. Trabecular bone is determined using peel mode 4 with a threshold of 655 mg/cm3 to distinguish (sub)cortical from cancellous bone. An additional concentric peel of 1% of the defined cancellous bone is used to ensure that (sub)cortical bone is 10 eliminated from the analysis. Volumetric content, density, and area are determined for both trabecular and cortical bone (Jamsa T. et al., Bone 23:155-161, 1998; Ke, H.Z. et al., Journal of Bone and Mineral Research, 16:765-773, 2001). <br><br> Vaginal histology: Vaginal tissue is fixed and embedded in paraffin. Five micron sections are cut and stained with Alcian Blue staining. Histology examination of vaginal 15 luminal epithelial thickness and mucopolysaccharide (secreted cells) is performed. The experimental groups for the protocol are as follows: <br><br> Group I:Baseline controls Group II: Sham + Vehicle <br><br> Group III: OVX + Vehicle 20 Group IV: OVX + Test Compound at 10 mg/kg/day (in Vehicle) <br><br> (2) Fracture Healing Assays <br><br> (a) Assay For Effects On Fracture Healing After Systemic Administration Fracture Technigue: Sprage-Dawley rats at 3 months of age are anesthetized with 25 Ketamine. A 1 cm incision is made on the anteromedial aspect of the proximal part of the right tibia or femur. The following describes the tibial surgical technique. The incision is carried through to the bone, and a 1 mm hole is drilled 4 mm proximal to the distal aspect of the tibial tuberosity 2 mm medial to the anterior ridge. Intramedullary nailing is performed with a 0.8 mm stainless steel tube (maximum load 36.3 N, maximum stiffness 61.8 N/mm, tested under 30 the same conditions as the bones). No reaming of the medullary canal is performed. A standardized closed fracture is produced 2 mm above the tibiofibular junction by three-point bending using specially designed adjustable forceps with blunt jaws. To minimize soft tissue damage, care is taken not to displace the fracture. The skin is closed with monofilament nylon sutures. The operation is performed under sterile conditions. Radiographs of all fractures are 35 taken immediately after nailing, and rats with fractures outside the specified diaphyseal area or with displaced nails are excluded. The remaining animals are divided randomly into the following groups with 10-12 animals per each subgroup per time point for testing the fracture <br><br> -78- <br><br> healing. The first group receives daily gavage of vehicle (water: 100% Ethanol = 95 : 5) at 1 ml/rat, while the others receive daily gavage from 0.01 to 100 mg/kg/day of the compound to be tested (1 ml/rat) for 10, 20, 40 and 80 days. <br><br> At 10, 20, 40 and 80 days, 10-12 rats from each group are anesthetized with 5 Ketamine and sacrificed by exsanguination. Both tibiofibular bones are removed by dissection and all soft tissue is stripped. Bones from 5-6 rats for each group are stored in 70% ethanol for histological analysis, and bones from another 5-6 rats for each group are stored in a buffered Ringer's solution (+4°C, pH 7.4) for radiographs and biomechanical testing which is performed. <br><br> 10 Histological Analysis: The methods for histologic analysis of fractured bone have been previously published by Mosekilde and Bak (The Effects of Growth Hormone on Fracture Healing in Rats: A Histological Description. Bone, 14:19-27, 1993). Briefly, the fracture site is sawed 8 mm to each side of the fracture line, embedded undecalcified in methymethacrylate, and cut frontals sections on a Reichert-Jung Polycut microtome in 8 |jm 15 thick. Masson-Trichrome stained mid-frontal sections (including both tibia and fibula) are used for visualization of the cellullar and tissue response to fracture healing with and without treatment. Sirius red stained sections are used to demonstrate the characteristics of the callus structure and to differentiate between woven bone and lamellar bone at the fracture site. The following measurements are performed: (1) fracture gap - measured as the shortest distance 20 between the cortical bone ends in the fracture, (2) callus length and callus diameter, (3) total bone volume area of callus, (4) bony tissue per tissue area inside the callus area, (5) fibrous tissue in the callus, and (6) cartilage area in the callus. <br><br> Biomechanical Analysis: The methods for biomechanical analysis have been previously published by Bak and Andreassen (The Effects of Aging on Fracture Healing in 25 Rats. Calcif Tissue Int 45:292-297, 1989). Briefly, radiographs of all fractures are taken prior to the biomechanical test. The mechanical properties of the healing fractures are analyzed by a destructive three- or four-point bending procedure. Maximum load, stiffness, energy at maximum load, deflection at maximum load, and maximum stress are determined. <br><br> 30 (b) Assay for Effects on Fracture Healing After Local Administration <br><br> Fracture Technigue: Female or male beagle dogs at approximately 2 years of age are used under anesthesia in the study. Transverse radial fractures are produced by slow continuous loading in three-point bending as described by Lenehan et al. (Lenehan, T. M.; Balligand, M.; Nunamaker, D.M.; Wood, F.E.: Effects of EHDP on Fracture Healing in Dogs. J 35 Orthop Res 3:499-507; 1985). A wire is pulled through the fracture site to ensure complete anatomical disruption of the bone. Thereafter, local delivery of prostaglandin agonists to the fracture site is achieved by slow release of compound delivered by slow release pellets or by <br><br> -79- <br><br> administration of the compounds in a suitable formulation such as a paste gel solution or suspension for 10, 15, or 20 weeks. <br><br> Histological Analysis: The methods for histologic analysis of fractured bone have been previously published by Peter et al. (Peter, C.P.; Cook, W.O.; Nunamaker, D.M.; <br><br> 5 Provost, M. T.; Seedor, J.G.; Rodan, G.A. Effects of alendronate on fracture healing and bone remodeling in dogs. J. Orthop. Res. 14:74-70, 1996) and Mosekilde and Bak (The Effects of Growth Hormone on Fracture Healing in Rats: A Histological Description. Bone, 14:19-27, 1993). Briefly, after sacrifice, the fracture site is sawed 3 cm to each side of the fracture line, embedded undecalcified in methymethacrylate, and cut on a Reichert-Jung Polycut 10 microtome in 8 |jm thick of frontal sections. Masson-Trichrome stained mid-frontal sections (including both tibia and fibula) are used for visualization of the cellullar and tissue response to fracture healing with and without treatment. Sirius red stained sections are used to demonstrate the characteristics of the callus structure and to differentiate between woven bone and lamellar bone at the fracture site. The following measurements are performed: (1) 15 fracture gap - measured as the shortest distance between the cortical bone ends in the fracture, (2) callus length and callus diameter, (3) total bone volume area of callus, (4) bony tissue per tissue area inside the callus area, (5) fibrous tissue in the callus, (6) cartilage area in the callus. <br><br> Biomechanical Analysis: The methods for biomechanical analysis have been 20 previously published by Bak and Andreassen (The Effects of Aging on Fracture Healing in Rats. Calcif Tissue Int 45:292-297, 1989) and Peter et al. (Peter, C.P.; Cook, W.O.; Nunamaker, D.M.; Provost, M. T.; Seedor, J.G.; Rodan, G.A. Effects of Alendronate On Fracture Healing And Bone Remodeling In Dogs. J. Orthop. Res. 14:74-70, 1996). Briefly, radiographs of all fractures are taken prior to the biomechanical test. The mechanical 25 properties of the healing fractures are analyzed by a destructive three- or four-point bending procedures. Maximum load, stiffness, energy at maximum load, deflection at maximum load, and maximum stress are determined. <br><br> Administration of the compounds described herein (hereinafter the "active compound(s)") can be effected by any method that enables delivery of the compounds to the 30 site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical, and rectal administration. <br><br> The amount of the active compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the 35 disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this <br><br> -80- <br><br> would amount to about 0.05 to about 7 g/day, preferably about 0.2 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses 5 for administration throughout the day. <br><br> The active compound may be applied as a sole therapy or may involve one or more other anti-tumour substances, for example those selected from, for example, mitotic inhibitors, for example vinblastine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; anti-metabolites, for example 5-fluorouracil, cytosine arabinoside and 10 hydroxyurea, or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No. 239362 such as N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid; growth factor inhibitors; cell cycle inhibitors; intercalating antibiotics, for example adriamycin and bleomycin; enzymes, for example interferon; and anti-hormones, for example anti-estrogens such as Nolvadex 15 (tamoxifen) or, for example anti-androgens such as Casodex (4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide). Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. <br><br> The pharmaceutical composition may, for example, be in a form suitable for oral 20 administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical 25 carrier or excipient and a compound described herein as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc. <br><br> Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired. <br><br> 30 Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents. The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with 35 binding agents such as sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin <br><br> -81- <br><br> capsules. Preferred materials, therefor, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration the active compound therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending 5 agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof. <br><br> Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent, to those skilled in this art. For examples, see Remington's Pharmaceutical Sciences. Mack Publishing Company, Easter, Pa., 15th 10 Edition (1975). <br><br> The examples and preparations provided below further illustrate and exemplify the compounds and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. In the following examples molecules with a single chiral center, unless 15 otherwise noted, exist as a racemic mixture. Those molecules with two or more chiral centers, unless otherwise noted, exist as a racemic mixture of diastereomers. Single enantiomers/diastereomers may be obtained by methods known to those skilled in the art. <br><br> Where HPLC chromatography is referred to in the preparations and examples below, the general conditions used, unless otherwise indicated, are as follows. The column used is a 20 ZORBAX™ RXC18 column (manufactured by Hewlett Packard) of 150 mm distance and 4.6 mm interior diameter. The samples are run on a Hewlett Packard-1100 system. A gradient solvent method is used running 100 percent ammonium acetate / acetic acid buffer (0.2 M) to 100 percent acetonitrile over 10 minutes. The system then proceeds on a wash cycle with 100 percent acetonitrile for 1.5 minutes and then 100 percent buffer solution for 3 minutes. 25 The flow rate over this period is a constant 3 ml. / minute. <br><br> Examples <br><br> General Methods: <br><br> Preparation of 5-nitro-oxindole: <br><br> 30 To a solution of oxindole (26 g) in 100 ml. of concentrated sulfuric acid at -15"C was added fuming nitric acid (8.4 ml.) dropwise. Careful attention was paid to maintain the reaction temperature at -15"C. After the addition was complete, the reaction was stirred for 30 minutes and then poured into ice water. A yellow precipitate was formed which was isolated by filtration to provide 34 grams (98%) of 5-nitro oxindole. <br><br> 35 Preparation of 5-amino-oxindole (2): <br><br> To a solution of 5-nitro-oxindole (25 g) in 120 ml. of dimethylacetamide in a Parr bottle was added 10% Pd/C (0.5 g). The mixture was hydrogenated (40 psi H2) for 16 hours. <br><br> -82- <br><br> The catalyst was removed by filtration and the filtrate was diluted with ether (2L) to provide 5-amino-oxindole (10.5 g; 50%). <br><br> Preparation of 2,4-dichloro-5-trifluoromethvlpyrimidine (3): <br><br> 5-Trifluoromethyluracil (250g, 1.39 mol) and phosphorous oxychloride (655 ml_, 6.94 5 mol, 5 equiv) were charged to a 3L 4-neck flask equipped with overhead stirrer, a reflux condenser, an addition funnel and an internal theromocouple. The contents were maintained under a nitrogen atmosphere as concentrated phosphoric acid (85 wt%, 9.5 ml_, 0.1 equiv) was added in one portion to the slurry, resulting in a moderate exotherm. Diisopropylethylamine (245 ml_, 1.39 mol, 1 equiv) was then added dropwise over 15 minutes 10 at such a rate that the internal temperature of the reaction reached 85-90'C by the end of the addition. By the end of the amine addition the reaction mixture was a homogenous light-orange solution. Heating was initiated and the orange solution was maintained at lOO'C for 20 hours, at which time HPLC analysis of the reaction mixture indicated that the starting material was consumed. External heating was removed and the contents of the flask were 15 cooled to 40^ and then added dropwise to a cooled mixture of 3N HCI (5 L, 10 equiv) and diethyl ether (2L) keeping the temperature of the quench pot between 10 and 15"C. The layers were separated, and the aqueous layer was extracted once with ether (1L). The combined organic layers were combined, washed with water until the washes were neutral (5 x 1.5L washes), dried with MgS04 and concentrated to provide 288g (95% yield) of a light 20 yellow-orange oil of 96% purity (HPLC). This material can be further purified by distillation (bp 109^ at 79 mmHg). <br><br> Preparation of 5-(4-Chloro-5-trifluoromethvl-pyrimidin-2-vlamino)-1,3-dihvdro-indol-2- <br><br> one (4): <br><br> To a solution of 5-trifluoromethyl-2,4-dichloropyrimidine (214.8 g; 0.921 mol) in 1:1 25 DCE/tBuOH (1.240 L) was added Zinc chloride 1M solution in ether (1 eq; 0.921 L). After 0.5 hour, 5-amino-oxindole (124 g; 0.837 mol) was added followed by triethylamine (129.4 ml; 0.921 mol) keeping temperature at 25^. The reaction was allowed to stir at room temperature overnight, then was concentrated and the product triturated from methanol as a yellow solid (224.3 g; 82%). 1H NMR (DMSO-d6, 400 MHz) . 3.29 (s, 2H), 6.76 (d, J = 7.9 Hz, 30 2H), 7.39 (d, J = 8.3 Hz), 7.51 (br s, 1H), 8.71 (s, 1H), 10.33 (s, 1H), 10.49 (s, 1H). 13C NMR (DMSO-de, 100 MHz) 177.0, 161.3, 158.7 (br), 140.7, 132.8, 126.9, 123.7 (q, J = 268 Hz), <br><br> 121.0, 118.7, 111.2 (q, J = 32 Hz), 109.6, 36.7; HPLC ret. time: 5.759 min. LRMS (M+) <br><br> 329.1, 331.1. <br><br> Example 1 <br><br> 35 5-[4-(R-1-Phenvl-ethvlamino)-5-trifluoromethvl-pyrimidin-2-vlamino1-1,3-dihvdro-indol-2-one <br><br> -83- <br><br> 5 <br><br> 10 <br><br> 15 <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> N-(1-Methyl-1-phenyl-ethyl)-3-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-benzenesulfonamide <br><br> 6.46 <br><br> 597.5 <br><br> 3-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-benzenesulfonamide <br><br> 4.87 <br><br> 479.1 <br><br> 5-{4-[3-(Trifluoro-methanesulfonyl)-benzylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 6.35 <br><br> 532.1 <br><br> 5-{4-[(Piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 3.74 <br><br> 407.3 <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.21 <br><br> 485.2 <br><br> N-(3-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.22 <br><br> 493.3 <br><br> X—N O H <br><br> To a solution of 1:1 DCE/t-BuOH alcohol (1:1 ratio, 4 mL) and 5-(4-Chloro-5-trifluoromethyl-pyrimdin-2-ylamino)-1,3-dihydro-indol-2-one (0.15 g; 0.456 mmole) was added (R)(+) alpha phenethyl amine (0.071 mL; 0.547 mmole) and diisopropyl ethyl amine (0.081 mL, 0.456 mmole). The resultant solution was stirred under nitrogen and heated to 80'C for 16 hours. The reaction was cooled to room temperature, diluted with ~10 mL of a 1:1 mixture of dichloromethane and methanol followed by the addition of 0.5 g of MP-carbonate. The resultant mixture was stirred, filtered, concentrated and purified by silica gel chromatography (97:2.8:0.3 ratio of chloroform/methanol/concentrated ammonium hydroxide). The desired title compounds was obtained as a white solid (0.021 g; 11%). HPLC ret. time: 6.46 min. LRMS (M+) 413.4 <br><br> The following compounds were prepared by heating chloropyrimidine (4) with an appropriate amine as in Example 1. Amines used in these reactions were either obtained commercially and used as received or alternatively they were prepared by common synthetic methods for amines known to those skilled in the art. Unless otherwise noted, compounds having chiral centers were prepared as racemic mixtures. <br><br> Table 1. Compounds Prepared by the Method of Example 1: <br><br> -84- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> 3-Oxo-3-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-piperidin-1 -yl)-propionitrile <br><br> 4.92 <br><br> 474.3 <br><br> 5-{4-[3-(1,1 -Dioxo-1 Nb-isothiazolidin-2-yl)-propylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.89 <br><br> 471.1 <br><br> 5-[4-(2-Methyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.53 <br><br> 380.3 <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.17 <br><br> 485.3 <br><br> N-{2-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-methanesulfonamide <br><br> 4.38 <br><br> 431.2 <br><br> N-{4-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-butyl}-methanesulfonamide <br><br> 4.78 <br><br> 459.3 <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.22 <br><br> 485.3 <br><br> N-Methyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-methanesulfonamide <br><br> 4.81 <br><br> 445.1 <br><br> Methanesulfonic acid 3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl ester <br><br> 5.67 <br><br> 494.1 <br><br> N-{3-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide <br><br> 4.58 <br><br> 445.1 <br><br> 5-{4-[(4-Methanesulfonyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.87 <br><br> 487.2 <br><br> N-(4-Fluoro-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.29 <br><br> 511.1 <br><br> 5-{4-[(5-Oxo-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 4.12 <br><br> 423.3 <br><br> N-(4-Methoxy-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.38 <br><br> 523.2 <br><br> N-(4-Methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.30 <br><br> 507.2 <br><br> 5-[4-(3-Methanesulfonylmethyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.14 <br><br> 492.2 <br><br> 5-{4-[(4-Trifluoroacetyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.64 <br><br> 505.1 <br><br> -85- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> 5-{4-[(1-Methanesulfonyl-azetidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.76 <br><br> 457.2 <br><br> N-Methyl-N-(4-methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 6.66 <br><br> 521.3 <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.97 <br><br> 471.2 <br><br> N-Methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide <br><br> 5.02 <br><br> 459.2 <br><br> 5-{4-[2-(1-Methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.71 <br><br> 499.4 <br><br> 5-{4-[(4-Methanesulfonyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.68 <br><br> 479.1 <br><br> {2,2-Dimethyl-3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-carbamic acid tert-butyl ester <br><br> 7.01 <br><br> 495.0 <br><br> 5-[4-(3-lsopropoxy-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 6.27 <br><br> 410.4 <br><br> 5-{4-[(1-Methyl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 3.71 <br><br> 421.0 <br><br> 5-{4-[(Tetrahydro-pyran-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.16 <br><br> 408.3 <br><br> 5-[4-(2-Ethyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.95 <br><br> 394.3 <br><br> 5-{4-[(Tetrahydro-furan-2R-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.30 <br><br> 394.3 <br><br> 5-{4-[(Tetrahydro-furan-2S-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.30 <br><br> 394.3 <br><br> 5-{4-[(5-Methyl-furan-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.98 <br><br> 404.2 <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.08 <br><br> 471.3 <br><br> 5-{4-[(Adamantan-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 7.89 <br><br> 458.3 <br><br> 5-{4-[(Adamantan-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.20 <br><br> 473.3 <br><br> -86- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> 5-[4-(2-Methoxy-2-methyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.87 <br><br> 396.3 <br><br> 5-{4-[(e/7c/o-Bicyclo[2.2.1]hept-5-en-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 6.74 <br><br> 416.3 <br><br> (3-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-benzyl)-phosphonic acid dimethyl ester <br><br> 5.03 <br><br> 522.2 <br><br> 5-[4-(3-Methyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.87 <br><br> 380.2 <br><br> 5-{4-[(2-Hydroxy-cyclohexylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 6.66 <br><br> 422.2 <br><br> N-(4-Methoxy-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide <br><br> 5.69 <br><br> 537.2 <br><br> 5-{4-[(4-Ethanesulfonyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.11 <br><br> 501.3 <br><br> 5-(4-{[4-(Propane-2-sulfonyl)-morpholin-2-ylmethyl]-amino}-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 5.35 <br><br> 515.2 <br><br> 5-{4-[(4-Acetyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 4.43 <br><br> 451.2 <br><br> 5-{4-[(4-Propionyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol- <br><br> 2-o ne <br><br> 4.74 <br><br> 465.2 <br><br> 5-(4-{[4-(2,2-Dimethyl-propionyl)-morpholin-2-ylmethyl]-amino}-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 5.43 <br><br> 493.2 <br><br> 2-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-morpholine-4-carboxylic acid methyl ester <br><br> 5.04 <br><br> 467.2 <br><br> 5-{4-[(4-Methoxyacetyl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.44 <br><br> 481.2 <br><br> 5-[4-(3-Ethanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.36 <br><br> 492.3 <br><br> 5-{4-[(4-Methanesulfonyl-morpholin-2R-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.84 <br><br> 487.3 <br><br> 5-{4-[(4-Methanesulfonyl-morpholin-2S-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.86 <br><br> 487.3 <br><br> 5-{4-[(Pyrimidin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 4.53 <br><br> 402.3 <br><br> -87- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> 5-{4-[(Pyrazin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 4.42 <br><br> 402.1 <br><br> N-(4-Fluoro-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide <br><br> 5.55 <br><br> 523.3 <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.17 <br><br> 485.3 <br><br> 5-{4-[(4-lsobutyryl-morpholin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.03 <br><br> 479.2 <br><br> 5-[4-(3,3-Dimethyl-2-oxo-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 6.00 <br><br> 408.2 <br><br> 5-[4-(1,2-Dimethyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 6.65 <br><br> 380.3 <br><br> 5-[4-(2-Methoxy-1-methyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.57 <br><br> 382.3 <br><br> 5-{4-[2-(1,1 -Dioxo-1 D°-isothiazolidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.59 <br><br> 457.3 <br><br> 5-[4-(3-Methylamino-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 3.47 <br><br> 381.3 <br><br> 5-{4-[(Pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 4.62 <br><br> 401.3 <br><br> 5-{4-[(6-Methanesulfonyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.89 <br><br> 479.3 <br><br> 5-{4-[3-(1,1-Dioxo-1 ,l,6-isothiazolidin-2-yl)-benzylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.45 <br><br> 519.2 <br><br> 5-[4-(1R-Phenyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.42 <br><br> 414.4 <br><br> 5-(4-lsopropylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 5.84 <br><br> 352.2 <br><br> 5-(4R-sec-Butylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 6.22 <br><br> 366.2 <br><br> 5-(4S-sec-Butylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 6.23 <br><br> 366.2 <br><br> 5-[4-(2-Methylamino-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 3.29 <br><br> 367.3 <br><br> 5-[4-(1S-Phenyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.42 <br><br> 414.3 <br><br> 5-{4-[(2-Methanesulfonylmethyl-thiazol-4- <br><br> 4.72 <br><br> 499.3 <br><br> -88- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5-(4-Propylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 5.91 <br><br> 352.2 <br><br> 5-[4-(2-Hydroxy-1-methyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 4.49 <br><br> 368.2 <br><br> 5-[4-(1-Hydroxymethyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 4.85 <br><br> 382.2 <br><br> 5-{4-[(5-Methanesulfonyl-pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.55 <br><br> 479.4 <br><br> 5-{4-[(Pyridin-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 4.49 <br><br> 401.2 <br><br> 5-[4-(1,3-Dimethyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.99 <br><br> 394.3 <br><br> N-lsopropyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide <br><br> 5.12 <br><br> 487.3 <br><br> 5-[4-(1S-Hydroxymethyl-2-methyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol- <br><br> 2-o ne <br><br> 5.23 <br><br> 396.3 <br><br> N-Cyclohexyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide <br><br> 6.24 <br><br> 527.2 <br><br> 5-[4-(1,2,3,4-Tetrahydro-naphthalen-1-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol- <br><br> 2-o ne <br><br> 440.4 <br><br> 7.17 <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-2S-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.07 <br><br> 471.2 <br><br> 5-{4-[(3-Methyl-thiophen-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 6.18 <br><br> 420.4 <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-3R-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.95 <br><br> 471.2 <br><br> 5-[4-(2-Hydroxy-1S-phenyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.28 <br><br> 430.3 <br><br> 5-[4-(2-Hydroxy-1S-methyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 4.49 <br><br> 368.3 <br><br> 5-[4-(1R-Hydroxymethyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 4.85 <br><br> 382.2 <br><br> 5-[4-(1-Pyrimidin-4-yl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> 4.84 <br><br> 416.3 <br><br> -89- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> one <br><br> 5-[4-(1,1 -Dioxo-tetrahydro-1 -thiophen-3-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 4.67 <br><br> 426.3 <br><br> 5-{4-[(1H-lmidazol-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 3.27 <br><br> 390.3 <br><br> 5-[4-(2-Piperidin-2-yl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 3.79 <br><br> 421.4 <br><br> 5-[4-(lsobutyl-methyl-amino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.82 <br><br> 380.3 <br><br> N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.49 <br><br> 507.4 <br><br> N-Ethyl-N-(3-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.67 <br><br> 521.3 <br><br> 5-[4-(2-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.47 <br><br> 478.2 <br><br> N-lsopropyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.81 <br><br> 535.3 <br><br> 5-{4-[(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.79 <br><br> 484.3 <br><br> 5-{4-[(1-Pyrimidin-2-yl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 6.17 <br><br> 485.3 <br><br> 5-{4-[2R-(1-Methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.70 <br><br> 499.4 <br><br> 5-{4-[2S-(1-Methanesulfonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.70 <br><br> 499.4 <br><br> 5-[4-(3-Methylsulfanyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.83 <br><br> 398.2 <br><br> 5-[4-(1S-Hydroxymethyl-3-methylsulfanyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 5.02 <br><br> 428.2 <br><br> 5-[4-(2-Hydroxy-1R-methyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 4.49 <br><br> 368.3 <br><br> 5-[4-(1R-Hydroxymethyl-2-methyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol- <br><br> 2-o ne <br><br> 5.23 <br><br> 396.4 <br><br> N-Ethyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}- <br><br> 5.31 <br><br> 473.3 <br><br> -90- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> methanesulfonamide <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-3R-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.94 <br><br> 471.4 <br><br> 5-[4-(1S-Hydroxymethyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 4.86 <br><br> 382.3 <br><br> 5-[4-(3,5-Dinitro-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.04 <br><br> 490.1 <br><br> N-(2-{[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.84 <br><br> 493.1 <br><br> N-lsopropyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-methanesulfonamide <br><br> 5.37 <br><br> 473.3 <br><br> 5-[4-(2-Hydroxy-1-phenyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.29 <br><br> 430.3 <br><br> 5-[4-(1R-Hydroxymethyl-3-methyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.59 <br><br> 410.4 <br><br> 5-[4-(1S-Hydroxymethyl-3-methyl-butylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.59 <br><br> 410.4 <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-2S-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.16 <br><br> 485.3 <br><br> 5-{4-[(1-Methanesulfonyl-pyrrolidin-2R-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.08 <br><br> 471.3 <br><br> 5-[4-(Methyl-pyridin-2-ylmethyl-amino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.37 <br><br> 415.3 <br><br> 5-{4-[(3-Methanesulfonyl-benzyl)-methyl-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol- <br><br> 2-o ne <br><br> 5.66 <br><br> 492.3 <br><br> N-Methyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.63 <br><br> 507.3 <br><br> 5-[4-(Methyl-pyridin-3-ylmethyl-amino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.25 <br><br> 415.4 <br><br> 5-{4-[(1-Methanesulfonyl-piperidin-3-ylmethyl)-methyl-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.69 <br><br> 499.4 <br><br> 5-[4-(Methyl-pyridin-4-ylmethyl-amino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.12 <br><br> 415.3 <br><br> 5-(4-Cyclopentylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 6.47 <br><br> 378.3 <br><br> -91- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> 5-[4-(2,6-Dimethoxy-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 6.78 <br><br> 460.3 <br><br> 5-{4-[(1,5-Dimethyl-1 H-pyrazol-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.99 <br><br> 418.3 <br><br> 5-[4-(2-lmidazol-1-yl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 3.58 <br><br> 404.2 <br><br> 5-{4-[(Pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 4.95 <br><br> 401.4 <br><br> 5-[5-Trifluoromethyl-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 6.57 <br><br> 468.2 <br><br> 5-{4-[(3-Methyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 6.07 <br><br> 415.3 <br><br> 5-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.16 <br><br> 478.2 <br><br> 5-{4-[2-(1-Acetyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.22 <br><br> 463.4 <br><br> 5-{4-[2-(1-Propionyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol- <br><br> 2-o ne <br><br> 5.65 <br><br> 477.4 <br><br> 5-{4-[2-(1-Cyclopropanecarbonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.86 <br><br> 489.4 <br><br> 5-{4-[2-(1-lsobutyryl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol- <br><br> 2-o ne <br><br> 6.07 <br><br> 491.3 <br><br> 5-{4-[2-(1-Butyryl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.99 <br><br> 491.4 <br><br> 5-{4-[2-(1-Methoxyacetyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.19 <br><br> 493.4 <br><br> 5-{4-[2-(1-Cyclobutanecarbonyl-piperidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 6.31 <br><br> 503.4 <br><br> N-Methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-acetamide <br><br> 4.47 <br><br> 423.3 <br><br> N-Methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-propionamide <br><br> 4.89 <br><br> 437.45 <br><br> Cyclopropanecarboxylic acid methyl-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl- <br><br> 5.07 <br><br> 449.3 <br><br> -92- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> pyrimidin-4-ylamino]-propyl}-amide <br><br> N-Methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-isobutyramide <br><br> 5.24 <br><br> 451.3 <br><br> N-Methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-butyramide <br><br> 5.25 <br><br> 451.4 <br><br> 2-Methoxy-N-methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-acetamide <br><br> 4.47 <br><br> 453.3 <br><br> Cyclobutanecarboxylic acid methyl-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-amide <br><br> 5.48 <br><br> 463.4 <br><br> 2,2,N-Trimethyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-propionamide <br><br> 5.80 <br><br> 465.3 <br><br> 2,N-Dimethyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-butyramide <br><br> 5.55 <br><br> 465.3 <br><br> N-Methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-benzamide <br><br> 5.38 <br><br> 485.3 <br><br> lsoxazole-5-carboxylic acid methyl-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-amide <br><br> 4.91 <br><br> 476.2 <br><br> Morpholine-4-carboxylic acid methyl-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-amide <br><br> 4.78 <br><br> 494.3 <br><br> Ethanesulfonic acid methyl-{3-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-amide <br><br> 5.29 <br><br> 473.3 <br><br> Propane-1-sulfonic acid methyl-{3-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-amide <br><br> 5.71 <br><br> 487.3 <br><br> 1,1,3-Trimethyl-3-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-sulfonylurea <br><br> 5.53 <br><br> 488.3 <br><br> 2,2,2-Trifluoro-N-methyl-N-{3-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-acetamide <br><br> 5.80 <br><br> 477.2 <br><br> N-Methyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-acetamide <br><br> 4.23 <br><br> 409.2 <br><br> N-Methyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-propionamide <br><br> 4.61 <br><br> 423.2 <br><br> Cyclopropanecarboxylic acid methyl-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-amide <br><br> 4.77 <br><br> 435.2 <br><br> N-Methyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5- <br><br> 4.94 <br><br> 437.2 <br><br> -93- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-isobutyramide <br><br> N-Methyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-butyramide <br><br> 4.95 <br><br> 437.2 <br><br> 2-Methoxy-N-methyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-acetamide <br><br> 4.21 <br><br> 439.2 <br><br> Cyclobutanecarboxylic acid methyl-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-amide <br><br> 5.17 <br><br> 449.3 <br><br> 2,2,N-Trimethyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-propionamide <br><br> 5.57 <br><br> 451.4 <br><br> 2,N-Dimethyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-butyramide <br><br> 5.26 <br><br> 451.4 <br><br> N-Methyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-benzamide <br><br> 4.80 <br><br> 471.3 <br><br> lsoxazole-5-carboxylic acid methyl-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-amide <br><br> 4.51 <br><br> 462.3 <br><br> Morpholine-4-carboxylic acid methyl-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-amide <br><br> 4.41 <br><br> 480.3 <br><br> N-Methyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-methanesulfonamide <br><br> 4.77 <br><br> 445.1 <br><br> Ethanesulfonic acid methyl-{2-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-amide <br><br> 5.03 <br><br> 459.2 <br><br> Propane-1-sulfonic acid methyl-{2-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-amide <br><br> 5.44 <br><br> 473.3 <br><br> 1,1,3-T ri methy l-3-{2-[2-(2-oxo-2,3-di hy d ro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-sulfonylurea <br><br> 5.49 <br><br> 474.2 <br><br> 2,2,2-Trifluoro-N-methyl-N-{2-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-acetamide <br><br> 5.49 <br><br> 463.2 <br><br> 5-[4-(2-Hydroxy-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 4.05 <br><br> 354.3 <br><br> 5-(4-Cyclopropylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 5.41 <br><br> 350.3 <br><br> 5-(4-Cyclobutylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 6.01 <br><br> 364.3 <br><br> 5-[4-(1,4-Dimethyl-pentylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 7.45 <br><br> 408.4 <br><br> -94- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> 5-[4-(3-lmidazol-1-yl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 3.77 <br><br> 418.3 <br><br> 5-[4-(2-Phenoxy-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.34 <br><br> 430.3 <br><br> 5-[4-(1-Cyclohexyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 7.61 <br><br> 420.4 <br><br> 5-[4-(1-Hydroxymethyl-2,2-dimethyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 5.64 <br><br> 410.4 <br><br> 5-[4-(1-Methoxymethyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.96 <br><br> 396.3 <br><br> 5-[4-(lndan-2-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.78 <br><br> 426.4 <br><br> 5-[4-(1,2,3,4-Tetrahydro-naphthalen-1-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol- <br><br> 2-o ne <br><br> 7.16 <br><br> 440.3 <br><br> 5-(4-Cycloheptylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 7.21 <br><br> 406.3 <br><br> 5-{4-[2-(2-Oxo-imidazolidin-1-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 4.04 <br><br> 422.3 <br><br> 4-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-butyric acid ethyl ester <br><br> 5.65 <br><br> 424.2 <br><br> 5-[4-(2-Hydroxy-1-hydroxy methyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 3.72 <br><br> 384.2 <br><br> 5-[4-(3-Hydroxy-2,2-dimethyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.09 <br><br> 396.3 <br><br> 5-{4-[(lsochroman-1-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 6.36 <br><br> 456.3 <br><br> 5-[4-(4-Hydroxy-1,1 -dioxo-tetrahydro-1 &amp;-thiophen-3-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 4.42 <br><br> 442.2 <br><br> 5-[4-(2-Methoxy-1-methyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.58 <br><br> 382.3 <br><br> 5-[4-(fra/7s-4-Methylsulfanyl-tetrahydro-furan-3-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 5.37 <br><br> 426.3 <br><br> 5-{4-[fra/7s-2-(Pyrimidin-2-ylsulfanyl)-cyclopentylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 6.32 <br><br> 488.3 <br><br> 5-[4-(lndan-1-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.86 <br><br> 426.3 <br><br> 5-{4-[2-(2-Hydroxy-ethylsulfanyl)-ethylamino]-5- <br><br> 4.66 <br><br> 414.3 <br><br> -95- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5-{4-[2-(Pyridin-3-yloxy)-propylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.20 <br><br> 445.3 <br><br> 5-{4-[2-(6-Methyl-pyridin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.00 <br><br> 429.3 <br><br> 5-{4-[(2,3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.01 <br><br> 458.2 <br><br> 5-{4-[(1-Methyl-1H-pyrazol-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 4.60 <br><br> 404.3 <br><br> 5-{4-[(4,5,6,7-Tetrahydro-benzothiazol-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.93 <br><br> 461.2 <br><br> 5-[4-(1-Phenyl-3-[1,2,4]triazol-1-yl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol- <br><br> 2-o ne <br><br> 5.24 <br><br> 495.2 <br><br> 5-(4-lsobutylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 6.12 <br><br> 366.4 <br><br> 5-[4-(2-Cyclohexyl-1-hydroxymethyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.41 <br><br> 450.4 <br><br> 2-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propionic acid methyl ester <br><br> 5.26 <br><br> 396.3 <br><br> 5-(4-Cyclohexylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 6.82 <br><br> 392.3 <br><br> 5-[4-(3-Hydroxy-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 4.24 <br><br> 368.3 <br><br> 5-{4-[2-(4-Methyl-1H-imidazol-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol- <br><br> 2-o ne <br><br> 3.54 <br><br> 418.3 <br><br> 5-[4-(Tetrahydro-furan-3-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 4.89 <br><br> 380.3 <br><br> 5-[4-(Dicyclopropylmethyl-amino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 6.59 <br><br> 404.3 <br><br> 5-{4-[2-(5-Methyl-4H-[1,2,4]triazol-3-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.00 <br><br> 419.3 <br><br> 5-[4-(2-Ethylsulfanyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.99 <br><br> 398.3 <br><br> 5-[4-(2-Phenoxy-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.57 <br><br> 444.2 <br><br> 5-{4-[(1-Ethyl-5-oxo-pyrrolidin-3-ylmethyl)- <br><br> 4.57 <br><br> 435.2 <br><br> -96- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5-(4-{[1-(2-Methoxy-ethyl)-5-oxo-pyrrolidin-3-ylmethyl]-amino}-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 4.44 <br><br> 465.2 <br><br> 5-[4-(Benzhydryl-amino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 7.26 <br><br> 476.2 <br><br> 5-{4-[2-(1-Methyl-1H-pyrazol-4-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol- <br><br> 2-o ne <br><br> 4.90 <br><br> 418.3 <br><br> 5-{4-[(4-Methyl-1H-imidazol-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol- <br><br> 2-o ne <br><br> 3.40 <br><br> 404.2 <br><br> 5-{4-[(5-Cyclopropyl-1H-pyrazol-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.00 <br><br> 430.2 <br><br> 5-{4-[2-(4-Methyl-thiazol-5-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.18 <br><br> 435.2 <br><br> 5-{4-[2-(1H-Benzoimidazol-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 4.39 <br><br> 454.2 <br><br> 5-{4-[(5-Methyl-[1,3,4]oxadiazol-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.25 <br><br> 406.3 <br><br> 5-{4-[(5-Phenyl-4H-[1,2,4]triazol-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.92 <br><br> 467.3 <br><br> 5-{4-[(1H-lndol-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 6.10 <br><br> 439.3 <br><br> 5-{4-[(1,5-Dimethyl-1 H-pyrazol-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.77 <br><br> 418.3 <br><br> 5-{4-[(Benzothiazol-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.77 <br><br> 457.2 <br><br> 5-{4-[(3-Methyl-isoxazol-5-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.02 <br><br> 405.3 <br><br> 5-{4-[(4-Methyl-thiazol-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.12 <br><br> 421.2 <br><br> 5-{4-[1-(4-Methyl-thiazol-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5.62 <br><br> 435.2 <br><br> 5-{5-Trifluoromethyl-4-[(1,3,5-trimethyl-1H-pyrazol-4-ylmethyl)-amino]-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.95 <br><br> 432.2 <br><br> 5-{4-[1-(2-Methyl-thiazol-4-yl)-ethylamino]-5- <br><br> 5.69 <br><br> 435.3 <br><br> -97- <br><br> Compound Name <br><br> HPLC <br><br> Retention Time (min.) <br><br> MS Data (M+H) <br><br> trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2- <br><br> one <br><br> 5-{4-[(3-Methyl-imidazo[2,1-b]thiazol-6-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.03 <br><br> 460.3 <br><br> 5-{4-[1-(5-Methyl-4H-[1,2,4]triazol-3-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.20 <br><br> 419.3 <br><br> 5-{4-[1-(3,5-Dimethyl-1H-pyrazol-4-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.02 <br><br> 432.3 <br><br> 5-{4-[2-(3,5-Dimethyl-1H-pyrazol-4-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.85 <br><br> 432.4 <br><br> 5-{4-[2-(4,6-Dimethyl-pyrimidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.17 <br><br> 444.4 <br><br> 5-{4-[2-(4-Methyl-5,6,7,8-tetrahydro-quinazolin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.88 <br><br> 484.4 <br><br> 5-[4-(2-Thiazol-4-yl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2- <br><br> one <br><br> 5.18 <br><br> 421.3 <br><br> 5-(4-Dimethylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 5.60 <br><br> 338.3 <br><br> 5-{4-[(1-Pyrimidin-2-yl-piperidin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 6.17 <br><br> 485.4 <br><br> 5-[4-(lndan-1-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 6.85 <br><br> 426.3 <br><br> Name <br><br> HPLC Ret <br><br> Time (min) <br><br> LRMS (MH+) <br><br> N-Methyl-N-{3-[({methyl-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-yl]-amino})-methyl]-phenyl}-methanesulfonamide <br><br> 6.08 <br><br> 521.3 <br><br> N-Methyl-N-{4-methyl-3-[({methyl-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-yl]-amino})-methyl]-phenyl}-methanesulfonamide <br><br> 6.24 <br><br> 535.8 <br><br> N-(5-Methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 6.23 <br><br> 507.2 <br><br> N-(3-Methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 6.28 <br><br> 507.2 <br><br> -98- <br><br> Name <br><br> HPLC Ret <br><br> Time (min) <br><br> LRMS (MH+) <br><br> N-(4-Methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 6.12 <br><br> 507.3 <br><br> N-(2-Methyl-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.71 <br><br> 507.3 <br><br> 5-[4-(3-Methanesulfonyl-propylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-o ne <br><br> 4.42 <br><br> 430.4 <br><br> N-Methyl-N-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.95 <br><br> 521.2 <br><br> N-(3-Methanesulfonylamino-5-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 4.85 <br><br> 586.2 <br><br> N-Methyl-N-(4-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.87 <br><br> 521.3 <br><br> N-Methyl-N-(2-methyl-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.86 <br><br> 521.3 <br><br> N-Methyl-N-(3-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.97 <br><br> 521.3 <br><br> 5-{4-[((1S,2R)-2-Hydroxy-cyclohexylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.56 <br><br> 422.3 <br><br> 5-[4-((1R,2S)-2-Hydroxy-indan-1-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-o ne <br><br> 5.66 <br><br> 442.4 <br><br> 5-[4-((S)-1-Hydroxymethyl-2-phenyl-ethylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 5.54 <br><br> 444.3 <br><br> N-(3-(Methanesulfonyl-methyl-amino)-5-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide <br><br> 5.36 <br><br> 614.2 <br><br> 5-{4-[(1-Hydroxy-cyclopentylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.2 <br><br> 408.2 <br><br> N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide <br><br> 5.26 <br><br> 508.2 <br><br> N-(3-Fluoro-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl- <br><br> 5.86 <br><br> 525.2 <br><br> -99- <br><br> Name <br><br> HPLC Ret <br><br> Time (min) <br><br> LRMS (MH+) <br><br> methanesulfonamide <br><br> 5-{4-[2-((S)-1-Methanesulfonyl-pyrrolidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.32 <br><br> 485.4 <br><br> 5-{4-[(1-Hydroxy-cyclobutylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.91 <br><br> 394.3 <br><br> 5-{4-[2-((R)-1-Methanesulfonyl-pyrrolidin-2-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.32 <br><br> 485.4 <br><br> N-(2-Fluoro-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide <br><br> 5.92 <br><br> 525.2 <br><br> N-(4-Fluoro-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide <br><br> 5.78 <br><br> 525.3 <br><br> N-Methyl-N-(4-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide <br><br> 5.17 <br><br> 508.1 <br><br> N-{2,2-Dimethyl-3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-N-methyl-methanesulfonamide <br><br> 5.7 <br><br> 487.3 <br><br> N-Methyl-N-(6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide <br><br> 5.61 <br><br> 508.2 <br><br> N-(2,4-Difluoro-6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-N-methyl-methanesulfonamide <br><br> 5.98 <br><br> 543.2 <br><br> 5-[4-((R)-1-Methanesulfonyl-piperidin-3-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 5.24 <br><br> 471.3 <br><br> N-Methyl-N-(6-methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide <br><br> 5.58 <br><br> 522.2 <br><br> N-Methyl-N-(5-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide <br><br> 4.79 <br><br> 508.2 <br><br> 5-[4-(1-Methanesulfonyl-piperidin-4-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 5.26 <br><br> 471.2 <br><br> 5-{4-[Methyl-((R)-1-phenyl-ethyl)-amino]-5- <br><br> trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 7.23 <br><br> 428.3 <br><br> 5-(4-Benzylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 6.05 <br><br> 400.3 <br><br> -100- <br><br> Name <br><br> HPLC Ret <br><br> Time (min) <br><br> LRMS (MH+) <br><br> N-(4,6-Dimethyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-N-methyl-methanesulfonamide <br><br> 6.1 <br><br> 536.3 <br><br> 5-(4-tert-Butylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 6.49 <br><br> 366.2 <br><br> 5-[4-((1R,5S,6S)-3-Methanesulfonyl-3-aza-bicyclo[3.1.0]hex-6-ylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 4.99 <br><br> 469.3 <br><br> N-Methyl-N-{3-methyl-3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-butyl}-methanesulfonamide <br><br> 5.7 <br><br> 487.2 <br><br> N-(6-Methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide <br><br> 5.27 <br><br> 508.2 <br><br> 5-{4-[(2-Methanesulfonyl-pyridin-4-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.79 <br><br> 479 <br><br> 2-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethanesulfonic acid amide <br><br> 4.19 <br><br> 417.1 <br><br> N-(3-{Methyl-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-yl]-amino}-propyl)-methanesulfonamide <br><br> 5.07 <br><br> 459.3 <br><br> N-(2-{Methyl-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-yl]-amino}-ethyl)-methanesulfonamide <br><br> 4.89 <br><br> 445.3 <br><br> 5-[4-(2-Methanesulfonylmethyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one <br><br> 5.38 <br><br> 492.3 <br><br> 2-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethanesulfonic acid dimethylamide <br><br> 5.09 <br><br> 445.2 <br><br> N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide <br><br> 5.49 <br><br> 509.2 <br><br> Ethanesulfonic acid methyl-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide <br><br> 5.96 <br><br> 521.3 <br><br> Ethanesulfonic acid (2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide <br><br> 6.23 <br><br> 507.2 <br><br> N-Ethyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide <br><br> 5.54 <br><br> 522.2 <br><br> N-{1,1 -Dimethyl-3-[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide <br><br> 5.18 <br><br> 473.1 <br><br> N-(5,6-Dimethyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-N-methyl- <br><br> 6.31 <br><br> 537.1 <br><br> -101- <br><br> Name <br><br> HPLC Ret <br><br> Time (min) <br><br> LRMS (MH+) <br><br> methanesulfonamide <br><br> 5-{4-[((R)-4-Methanesulfonyl-morpholin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.62 <br><br> 487.2 <br><br> Propane-1-sulfonic acid (2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide <br><br> 6.6 <br><br> 521.2 <br><br> 5-{4-[2-((R)-4-Methanesulfonyl-morpholin-3-yl)-ethylamino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 4.99 <br><br> 501.1 <br><br> Ethanesulfonic acid methyl-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-amide <br><br> 5.64 <br><br> 522.2 <br><br> Trifluoro-N-methyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide <br><br> 6.42 <br><br> 513.3 <br><br> Cyclopropanesulfonic acid methyl-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-amide <br><br> 5.5 <br><br> 485.3 <br><br> N-Ethyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 5.94 <br><br> 521.2 <br><br> Ethanesulfonic acid methyl-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide <br><br> Ethanesulfonic acid ethyl-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide <br><br> 6.22 <br><br> 535 <br><br> Ethanesulfonic acid ethyl-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide <br><br> 6.55 <br><br> 549 <br><br> N-Ethyl-N-(5-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 6.27 <br><br> 535.1 <br><br> Ethanesulfonic acid (5-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide <br><br> 6.59 <br><br> 521.1 <br><br> Ethanesulfonic acid (3-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide <br><br> 6.7 <br><br> 521.3 <br><br> Ethanesulfonic acid methyl-(3-methyl-2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-amide <br><br> 6.33 <br><br> 535.2 <br><br> 2-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethanesulfonic acid methylamide <br><br> 4.6 <br><br> 431.1 <br><br> Ethanesulfonic acid {3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4- <br><br> 4.87 <br><br> 459.1 <br><br> -102- <br><br> Name <br><br> HPLC Ret <br><br> Time (min) <br><br> LRMS (MH+) <br><br> ylamino]-propyl}-amide <br><br> C-Methanesulfonyl-N-{3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-methanesulfonamide <br><br> 4.84 <br><br> 523 <br><br> Ethanesulfonic acid {2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-amide <br><br> 4.65 <br><br> 445.2 <br><br> C-Methanesulfonyl-N-{2-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-ethyl}-methanesulfonamide <br><br> 4.62 <br><br> 509 <br><br> N-Methyl-N-(4-methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide <br><br> 5.63 <br><br> 522.1 <br><br> 5-(4-{[1-(2,2,2-Trifluoro-acetyl)-piperidin-3-ylmethyl]-amino}-5-trifluoromethyl-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one <br><br> 6.04 <br><br> 503.1 <br><br> 2,2,2-Trifluoro-ethanesulfonic acid {3-[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-propyl}-amide <br><br> 5.56 <br><br> 513.2 <br><br> N-Methyl-N-(4-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrimidin-2-yl)-methanesulfonamide <br><br> 5.21 <br><br> 509.3 <br><br> N-Cyclopropyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide <br><br> 6.01 <br><br> 533.3 <br><br> N-Methyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrimidin-4-yl)-methanesulfonamide <br><br> 4.95 <br><br> 509.2 <br><br> N-Methyl-N-(6-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide <br><br> 5.3 <br><br> 509.4 <br><br> N-Methyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide <br><br> 5.54 <br><br> 508.3 <br><br> N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-4-yl)-methanesulfonamide <br><br> 5.55 <br><br> 508.4 <br><br> N-Cyclopropyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide <br><br> 5.6 <br><br> 534.1 <br><br> N-Methyl-N-(6-methyl-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide <br><br> 5.93 <br><br> 523.4 <br><br> 5-{4-[(2-Methanesulfonylmethyl-pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one <br><br> 5.4 <br><br> 493.2 <br><br> N-Methyl-N-(4-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4- <br><br> 4.77 <br><br> 508.2 <br><br></p> </div>

Claims (6)

<div class="application article clearfix printTableText" id="claims"> <p lang="en"> -103-<br><br> Name<br><br> HPLC Ret<br><br> Time (min)<br><br> LRMS (MH+)<br><br> ylamino]-methyl}-pyridin-3-yl)-methanesulfonamide<br><br> The present invention is not to be limited in scope by the specific embodiments 5 described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.<br><br> All patents, applications, publications, test methods, literature, and other materials 10 cited herein are hereby incorporated herein by reference in their entireties.<br><br> -104-<br><br> WHAT WE CLAIM IS:<br><br>
1. A pharmaceutically acceptable salt of N-methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-<br><br> 5 methanesulfonamide.<br><br>
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and N-methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide or a pharmaceutically acceptable salt thereof.<br><br> 10
3. A use of N-methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-<br><br> trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer in a mammal.<br><br>
4. A pharmaceutically acceptable salt according to claim 1, substantially as 15 herein described with reference to any example thereof.<br><br>
5. A pharmaceutical composition according to claim 2, substantially as herein described with reference to any example thereof.<br><br>
6. A use according to claim 3, substantially as herein described with reference to any example thereof.<br><br> 20<br><br> </p> </div>
NZ550448A 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth NZ550448A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14
PCT/IB2005/001201 WO2005111023A1 (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
NZ550448A true NZ550448A (en) 2010-11-26

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ550448A NZ550448A (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Country Status (27)

Country Link
EP (1) EP1751143A1 (en)
JP (1) JP4099212B2 (en)
KR (1) KR100886990B1 (en)
CN (2) CN102127058A (en)
AP (1) AP2241A (en)
AR (1) AR049097A1 (en)
AU (2) AU2005243397A1 (en)
BR (1) BRPI0511138A (en)
CA (1) CA2566707A1 (en)
CR (1) CR8749A (en)
EA (1) EA200601796A1 (en)
EC (1) ECSP066997A (en)
GE (1) GEP20104875B (en)
GT (1) GT200500113A (en)
IL (1) IL178828A0 (en)
MA (1) MA28583B1 (en)
MX (1) MXPA06011890A (en)
NL (2) NL1029045C2 (en)
NO (1) NO20064576L (en)
NZ (1) NZ550448A (en)
PA (1) PA8632601A1 (en)
PE (1) PE20060240A1 (en)
TN (1) TNSN06370A1 (en)
TW (1) TWI303635B (en)
UY (1) UY28894A1 (en)
WO (1) WO2005111023A1 (en)
ZA (1) ZA200608394B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566531A1 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
JP4332590B2 (en) * 2005-12-21 2009-09-16 ファイザー・プロダクツ・インク Pyrimidine derivatives for treating abnormal cell proliferation
CN103951658B (en) * 2007-04-18 2017-10-13 辉瑞产品公司 Sulfamide derivative for treating abnormal cell growth
CN101903357A (en) * 2007-07-17 2010-12-01 里格尔药品股份有限公司 Cyclic amine substituted pyrimidinediamines as PKC inhibitors
JP2011505407A (en) * 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Diaminopyridine for treating diseases characterized by excessive or abnormal cell proliferation
HUE035029T2 (en) * 2008-05-21 2018-03-28 Ariad Pharma Inc Phosphorous derivatives as kinase inhibitors
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
JP5539518B2 (en) 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
JPWO2014174745A1 (en) * 2013-04-26 2017-02-23 国立大学法人京都大学 Eg5 inhibitor
CN109608444B (en) * 2018-11-27 2022-02-11 中国药科大学 Isoindolinone-containing ERK inhibitor and preparation method and application thereof
CN111732548B (en) * 2020-06-11 2022-06-17 浙江大学 N2-carbamyl aromatic ring-2-aminopyrimidine derivatives and medical application thereof
WO2024140671A1 (en) * 2022-12-29 2024-07-04 南京昕瑞再生医药科技有限公司 Fused tricyclic derivative, pharmaceutical composition comprising same, and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
RS20060097A (en) * 2002-12-20 2008-11-28 Pfizer Products Inc., Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
CN102127058A (en) 2011-07-20
EP1751143A1 (en) 2007-02-14
GEP20104875B (en) 2010-01-11
PA8632601A1 (en) 2006-06-02
JP4099212B2 (en) 2008-06-11
CN1953974A (en) 2007-04-25
IL178828A0 (en) 2007-03-08
MA28583B1 (en) 2007-05-02
AR049097A1 (en) 2006-06-28
KR20070012477A (en) 2007-01-25
NL1031845C2 (en) 2006-11-23
PE20060240A1 (en) 2006-04-01
TNSN06370A1 (en) 2008-02-22
AP2241A (en) 2011-06-01
TW200539871A (en) 2005-12-16
GT200500113A (en) 2006-01-10
NL1029045C2 (en) 2006-06-02
KR100886990B1 (en) 2009-03-04
CR8749A (en) 2006-12-05
BRPI0511138A (en) 2007-11-27
NO20064576L (en) 2006-11-07
ZA200608394B (en) 2008-05-28
EA200601796A1 (en) 2007-04-27
UY28894A1 (en) 2005-12-30
WO2005111023A1 (en) 2005-11-24
TWI303635B (en) 2008-12-01
NL1029045A1 (en) 2005-11-15
MXPA06011890A (en) 2006-12-14
ECSP066997A (en) 2007-02-28
CA2566707A1 (en) 2005-11-24
NL1031845A1 (en) 2006-07-31
JP2007537234A (en) 2007-12-20
AU2009238255A1 (en) 2009-12-03
AP2006003790A0 (en) 2006-10-31
AU2005243397A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
US7109337B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
US7208499B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
US7145008B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
JP4099212B2 (en) Pyrimidine derivatives for treating abnormal cell proliferation
EP1625121B1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
US7235562B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
US20060205945A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2016 BY COMPUTER PACKAGES INC

Effective date: 20150418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2017 BY COMPUTER PACKAGES INC

Effective date: 20160419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2018 BY COMPUTER PACKAGES INC

Effective date: 20170419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2019 BY COMPUTER PACKAGES INC

Effective date: 20180518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2020 BY COMPUTER PACKAGES INC

Effective date: 20190501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2021 BY COMPUTER PACKAGES INC

Effective date: 20200418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2022 BY COMPUTER PACKAGES INC

Effective date: 20210418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2023 BY COMPUTER PACKAGES INC

Effective date: 20220417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2024 BY COMPUTER PACKAGES INC

Effective date: 20230417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2025 BY COMPUTER PACKAGES INC

Effective date: 20240417